
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Synthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="FF20824F89B73D031A824F00284094BB.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="acsomega">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="ACS Omega">
<meta name="citation_title" content="Synthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias">
<meta name="citation_author" content="Melissa M Lewis-Bakker">
<meta name="citation_author_institution" content="Krembil Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario M5G 2L7, Canada">
<meta name="citation_author" content="Ewa Wasilewski">
<meta name="citation_author_institution" content="Krembil Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario M5G 2L7, Canada">
<meta name="citation_author" content="Melika Loriamini">
<meta name="citation_author_institution" content="Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A1, Canada">
<meta name="citation_author_institution" content="Centre for Innovation, Canadian Blood Services, Toronto, Ontario K1G 4J5, Canada">
<meta name="citation_author" content="Shengyu Wang">
<meta name="citation_author_institution" content="Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada">
<meta name="citation_author" content="Donald R Branch">
<meta name="citation_author_institution" content="Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A1, Canada">
<meta name="citation_author_institution" content="Centre for Innovation, Canadian Blood Services, Toronto, Ontario K1G 4J5, Canada">
<meta name="citation_author_institution" content="Department of Medicine, University of Toronto, Toronto, Ontario M5S 1A1, Canada">
<meta name="citation_author" content="Lakshmi P Kotra">
<meta name="citation_author_institution" content="Krembil Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario M5G 2L7, Canada">
<meta name="citation_author_institution" content="Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada">
<meta name="citation_author_institution" content="Ajmera Transplant Centre, University Health Network, Toronto General Hospital, 585 University Ave., Toronto, Ontario M5G 1L7, Canada">
<meta name="citation_publication_date" content="2025 Jul 25">
<meta name="citation_volume" content="10">
<meta name="citation_issue" content="30">
<meta name="citation_firstpage" content="33401">
<meta name="citation_doi" content="10.1021/acsomega.5c03645">
<meta name="citation_pmid" content="40787340">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/pdf/ao5c03645.pdf">
<meta name="description" content="Immune cytopenias are a group of autoimmune disorders where patients develop autoantibodies against certain types of blood cells such as red blood cells (RBCs) or thrombocytes. We investigated small molecules as potential inhibitors of phagocytosis ...">
<meta name="og:title" content="Synthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Immune cytopenias are a group of autoimmune disorders where patients develop autoantibodies against certain types of blood cells such as red blood cells (RBCs) or thrombocytes. We investigated small molecules as potential inhibitors of phagocytosis ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12332598">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1021/acsomega.5c03645"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/ao5c03645.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12332598%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12332598/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12332598/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-acsomega.png" alt="ACS Omega logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to ACS Omega" title="Link to ACS Omega" shape="default" href="https://pubs.acs.org/journal/acsodf" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">ACS Omega</button></div>. 2025 Jul 25;10(30):33401–33414. doi: <a href="https://doi.org/10.1021/acsomega.5c03645" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1021/acsomega.5c03645</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22ACS%20Omega%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22ACS%20Omega%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22ACS%20Omega%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22ACS%20Omega%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Synthesis and Biological Evaluation of Small Molecule
Inhibitors of Immune Cytopenias</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lewis-Bakker%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Melissa M Lewis-Bakker</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Melissa M Lewis-Bakker</span></h3>
<div class="p">
<sup>†</sup>
Krembil
Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario
M5G 2L7, Canada
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lewis-Bakker%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Melissa M Lewis-Bakker</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wasilewski%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ewa Wasilewski</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ewa Wasilewski</span></h3>
<div class="p">
<sup>†</sup>
Krembil
Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario
M5G 2L7, Canada
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wasilewski%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Ewa Wasilewski</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Loriamini%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Melika Loriamini</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Melika Loriamini</span></h3>
<div class="p">
<sup>‡</sup>
Department
of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario
M5S 1A1, Canada
</div>
<div class="p">
<sup>§</sup>
Centre
for Innovation, Canadian Blood Services, Toronto, Ontario
K1G 4J5, Canada
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Loriamini%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Melika Loriamini</span></a>
</div>
</div>
<sup>‡,</sup><sup>§</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Shengyu Wang</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Shengyu Wang</span></h3>
<div class="p">
<sup>∥</sup>
Department
of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario
M5S 3M2, Canada
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shengyu Wang</span></a>
</div>
</div>
<sup>∥</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Branch%20DR%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Donald R Branch</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Donald R Branch</span></h3>
<div class="p">
<sup>‡</sup>
Department
of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario
M5S 1A1, Canada
</div>
<div class="p">
<sup>§</sup>
Centre
for Innovation, Canadian Blood Services, Toronto, Ontario
K1G 4J5, Canada
</div>
<div class="p">
<sup>⊥</sup>
Department
of Medicine, University of Toronto, Toronto, Ontario
M5S 1A1, Canada
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Branch%20DR%22%5BAuthor%5D" class="usa-link"><span class="name western">Donald R Branch</span></a>
</div>
</div>
<sup>‡,</sup><sup>§,</sup><sup>⊥</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kotra%20LP%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Lakshmi P Kotra</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Lakshmi P Kotra</span></h3>
<div class="p">
<sup>†</sup>
Krembil
Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario
M5G 2L7, Canada
</div>
<div class="p">
<sup>∥</sup>
Department
of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario
M5S 3M2, Canada
</div>
<div class="p">
<sup>#</sup>
Ajmera
Transplant
Centre, University Health Network, Toronto
General Hospital, 585
University Ave., Toronto, Ontario
M5G 1L7, Canada
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kotra%20LP%22%5BAuthor%5D" class="usa-link"><span class="name western">Lakshmi P Kotra</span></a>
</div>
</div>
<sup>†,</sup><sup>∥,</sup><sup>#,</sup><sup>*</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>†</sup>
Krembil
Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario
M5G 2L7, Canada
</div>
<div id="aff2">
<sup>‡</sup>
Department
of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario
M5S 1A1, Canada
</div>
<div id="aff3">
<sup>§</sup>
Centre
for Innovation, Canadian Blood Services, Toronto, Ontario
K1G 4J5, Canada
</div>
<div id="aff4">
<sup>∥</sup>
Department
of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario
M5S 3M2, Canada
</div>
<div id="aff5">
<sup>⊥</sup>
Department
of Medicine, University of Toronto, Toronto, Ontario
M5S 1A1, Canada
</div>
<div id="aff6">
<sup>#</sup>
Ajmera
Transplant
Centre, University Health Network, Toronto
General Hospital, 585
University Ave., Toronto, Ontario
M5G 1L7, Canada
</div>
<div class="author-notes p"><div class="fn" id="cor1">
<sup>*</sup><p class="display-inline">
E-mail: <span>p.kotra@utoronto.ca</span>.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 21; Accepted 2025 Jul 21; Revised 2025 Jul 14; Collection date 2025 Aug 5.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Authors. Published by American Chemical Society</div>
<p>This article is licensed under CC-BY-NC-ND 4.0</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12332598  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40787340/" class="usa-link">40787340</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Immune cytopenias
are a group of autoimmune disorders where patients
develop autoantibodies against certain types of blood cells such as
red blood cells (RBCs) or thrombocytes. We investigated small molecules
as potential inhibitors of phagocytosis of blood cells that are prevalent
in immune thrombocytopenia (ITP) and warm autoantibody immune hemolytic
anemia (wAIHA). Upon screening a chemical library of over 13,000 compounds
in silico, followed by evaluating 80 compounds in vitro as inhibitors
of phagocytosis of opsonized RBCs by monocytes, we identified four
hit molecules. These compounds contain a pyrazole moiety as a key
structural feature. Here, we reveal the independent synthesis and
re-evaluation of these hits, as well as revalidate the biological
activities and the synthesis of their analogs to understand the structure–activity
relationships. Two of the resynthesized compounds showed up to a 9-fold
difference in their inhibitory activities between the commercial and
synthesized batches, and the analogs exhibited either equal or weaker
potency than the parent compounds targeting phagocytosis of RBCs.
The role of regioisomers and the importance of an ester moiety are
revealed as important structural features through these analogs. The
pharmacokinetics of the promising compound <strong>33</strong> suggested
that this compound shows significant efficacy in restoring platelet
counts in the mouse model of ITP, despite the rapid hydrolysis of
its methyl ester moiety.</p></section><section class="abstract" id="abstract2"><hr class="headless">
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/4b4b014272c8/ao5c03645_0011.jpg" loading="lazy" id="abs1" height="316" width="789" alt="graphic file with name ao5c03645_0011.jpg"></p></section><section class="abstract" id="abstract3"><hr class="headless">
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/4b4b014272c8/ao5c03645_0009.jpg" loading="lazy" id="tgr1" height="316" width="789" alt="graphic file with name ao5c03645_0009.jpg"></p></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Immune cytopenias are allo- and autoimmune
diseases defined by
blood cell destruction in the spleen and liver.<em>
−


</em> A large category of immune cytopenias
exists that target platelets, red blood cells (RBCs) and neutrophils,
including (i) immune thrombocytopenia (ITP; phagocytosis of autoantibody-coated
platelets); (ii) fetal and neonatal alloimmune thrombocytopenia (FNAIT;
maternal alloantibodies crossing the placenta to platelet antigens
on fetal or neonatal cells); (iii) warm autoantibody immune hemolytic
anemia (wAIHA; phagocytosis of autoantibody-coated red blood cells);
(iv) hemolytic transfusion reaction (HTR; phagocytosis of donor red
blood cells due to preformed hemolytic alloantibodies to the donor
red cell antigens); (v) delayed hemolytic transfusion reaction (DHTR;
development of hemolytic alloantibodies following transfusion); (vi)
hemolytic disease of the fetus and newborn (HDFN; maternal hemolytic
antibodies crossing the placenta); and (vii) autoimmune neutropenia
(AIN; associated with autoantibodies produced against neutrophils,
mainly affecting children).<em>
−

</em>
</p>
<p>ITP can be classified as
primary or secondary and has an incidence
of approximately 2–6 cases/100,000. Primary ITP, for an example,
is characterized by an isolated thrombocytopenia (absolute platelet
count &lt;100 × 10<sup>9</sup>/L) in the absence of any secondary
causes.<em>
,
</em> An increased risk of bleeding poses the
biggest clinical problem for primary ITP, however, bleeding symptoms
may not always be present.<em>
,
</em> On the other hand, secondary
ITP results from other manifestations, such as drugs, infections,
or diseases.<em>
,
</em>
</p>
<p>Under normal circumstances,
platelet production and clearance are
highly controlled processes. Platelets are produced in the bone marrow
courtesy of the hormone thrombopoietin (TPO), which is synthesized
in the liver.<em>
,
</em> Mature platelets lose sialic acid
from their surface and are physiologically cleared by the Ashwell–Morrell
receptor on liver cells, with platelet clearance leading to production
of new TPO. Additionally, apoptosis and
phagocytosis are involved in the platelet clearance. Thrombocytopenia may result from reduced production or
increased clearance/destruction of platelets and there are several
proposed mechanisms for the increased platelet clearance portrayed
in ITP. One proposed mechanism involves the presentation of platelet
antigens to B cells that differentiate into antibody-secreting plasma
cells and produce autoantibodies. Another
mechanism for platelet clearance involves phagocytosis mediated by
activating Fcγ receptors (FcγRI, FcγRIIA, FcγRIII).<em>
,
</em> Activated FcγRs activate Syk tyrosine kinase by downstream
signaling pathways.
</p>
<p>Another common
immune cytopenia is autoimmune hemolytic anemias,
having an incidence of approximately 1–2 cases/100,000, of
which there are nine different conditions. The most important of these conditions is wAIHA. wAIHA is caused
by an autoantibody to the patient’s autologous RBCs that is
pan-reactive with all unrelated RBCs; thus, causing difficulties in
finding compatible blood for transfusion into these individuals. It
has been shown that hemolysis is due to the phagocytosis of antibody-coated
RBCs by activating FcγRs.<em>
,
</em>
</p>
<p>The initial treatment
of ITP or wAIHA may involve administration
of corticosteroids (e.g., dexamethasone, prednisone) to increase platelet
and RBC counts,<em>
,
</em> or immunoglobulins [e.g., intravenous
immunoglobulin (IVIG)] for ITP patients
who are unresponsive to corticosteroids.<em>
,
</em> In Rh­(D)-positive patients, Rho­(D) immunoglobulin (anti-D) may be
used as a substitute to IVIG before splenectomy, a second-line treatment.<em>
,
</em> The most agreed-upon mechanism proposes that IVIG and anti-D work
by competitively inhibiting the FcγRs on the macrophages, reducing
their ability to recognize the Fc segment on the autoantibody binding
to the platelets or RBCs, therefore preventing phagocytosis.
</p>
<p>Despite the above treatments, effective
options for ITP or wAIHA,
or the other immune cytopenia, are quite limited and costly, with
poor response rates, high relapse rates, potential infusion reactions,
adverse events, such as hemolysis or thrombosis, longer treatment
durations, and poor tolerance. In addition to splenectomy for patients
with persistent thrombocytopenia or hemolytic anemias, other second-line treatments include Rituximab
(anti-CD20)a monoclonal antibody that targets B cells and
may be given before and after splenectomy.<em>
,
</em> Other drugs include spleen tyrosine kinase (Syk) inhibitors, and thrombopoietin receptor agonists (TPO-RAs)
which are specific for treatment of only ITP. The Syk inhibitor fostamatinib is a prodrug and is rapidly dephosphorylated
to its active metabolite R-406 (<a href="#cht1" class="usa-link">Chart 
</a>) in the stomach. The
mechanism of action of TPO-RAs such as avatrombopag and eltrombopag (<a href="#cht1" class="usa-link">Chart 
</a>) involves the stimulation
of the TPO receptors on megakaryocytes and hematopoietic pluripotent
stem cells, leading to increased platelet production.</p>
<figure class="fig xbox font-sm" id="cht1"><h3 class="obj_head">1. Current
Treatment Options for ITP
.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12332598_ao5c03645_0001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/93afea95a03c/ao5c03645_0001.jpg" loading="lazy" id="gr1" height="485" width="810" alt="1"></a></p>
<div class="p text-right font-secondary"><a href="figure/cht1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="cht1-fn1"><sup>a</sup> Fostamatinib is a Syk inhibitor
and is dephosphorylated to its active metabolite R-406. Avatrombopag
and Eltrombopag are TPO receptor agonists.</p></figcaption></figure><p>Small molecule drugs that prevent the phagocytosis of blood cells
such as platelets, RBCs will have a wider application for the treatment
of multiple immune cytopenias. These molecules could be administered
as the sole therapeutics or coadministered with other ITP treatment
options. Small molecules that would block phagocytosis via a different
mechanism than Syk inhibitors would provide a novel approach to the
treatment of all immune cytopenias.</p>
<p>Recently we reported the
in vitro evaluation of a library of 80
small molecules in an in vitro assay that mimics the phagocytosis
of antibody-opsonized RBCs, that occurs in the majority of immune
cytopenias. Four molecules, <strong>9c</strong>, <strong>19</strong>, <strong>33</strong>, and <strong>41</strong> (<a href="#cht2" class="usa-link">Chart 
</a>) exhibited &gt;69%
inhibition
of phagocytosis in a monocyte monolayer assay (MMA).<em>
,
</em>
</p>
<figure class="fig xbox font-sm" id="cht2"><h3 class="obj_head">2. Chemical Structures of the Four Active Hit Compounds and Their Anti-Phagocytosis
Activities.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12332598_ao5c03645_0002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/918e81ea9039/ao5c03645_0002.jpg" loading="lazy" id="gr2" height="247" width="807" alt="2"></a></p>
<div class="p text-right font-secondary"><a href="figure/cht2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>We herein report the resynthesis
of commercial chemical library
hits <strong>9c</strong>, <strong>19</strong>, <strong>33</strong>, and <strong>41</strong> for validation, synthesis of novel analogs and in vitro
activities in the MMA phagocytosis assays. A structure–activity
relationship was derived based on targeted modifications and the pharmacokinetics
of compound <strong>33</strong>, the most promising compound are discussed
in the context of efficacy in an ITP mouse model.</p></section><section id="sec2"><h2 class="pmc_sec_title">Results and Discussion</h2>
<section id="sec2.1"><h3 class="pmc_sec_title">Chemistry</h3>
<section id="sec2.1.1"><h4 class="pmc_sec_title">Synthesis
of <strong>9c</strong> and Analogs <strong>9a</strong>, <strong>9b</strong>, <strong>9d</strong>, and <strong>9e</strong>
</h4>
<p>The retrosynthetic
examination conducted on target hit compound <strong>9c</strong> (<a href="#sch1" class="usa-link">Scheme 
</a>A) indicated it could
be simplified into compounds <strong>5</strong> and <strong>8</strong>, which
can be coupled via amidation to afford <strong>9c</strong>. Intermediate <strong>8</strong> could be obtained via bromination of <strong>7</strong>, formed
from alkylation of commercially available <strong>6</strong>. Simultaneously, <strong>5</strong> could be generated from the pyrazole reaction of hydrazone <strong>4</strong>, obtained by a Japp–Klingeman reaction between aryl
diazonium <strong>2</strong> and commercially available β-keto ester <strong>3</strong>. However, the Japp–Klingeman reaction of <strong>3</strong> to produce <strong>4</strong> both failed using reported procedures.<em>
,
</em> Additionally, iodine-catalyzed reactions of phenylhydrazine and <strong>3</strong> (or ethyl-2-cyanoacetate) in DMSO to form <strong>4</strong> were also unsuccessful. This strategy
was revised as illustrated in <a href="#sch1" class="usa-link">Scheme 
</a>B, to synthesize <strong>9c</strong> and analogs. Intermediate <strong>4</strong> was synthesized from 2-cyano ethyl acetate <strong>3</strong> and compound <strong>2</strong> according to a modified procedure. Compound <strong>4</strong> and chloroacetonitrile
were refluxed in Et<sub>3</sub>N/EtOH to yield compound <strong>5</strong>, but the reaction was incomplete. However, microwave irradiation
in the presence of Et<sub>3</sub>N only led to the key intermediate <strong>5</strong> in moderate yields.</p>
<figure class="fig xbox font-sm" id="sch1"><h5 class="obj_head">1. Chemistry of Compounds <strong>9a</strong>, <strong>9b</strong>, <strong>9c</strong>, <strong>9d</strong>, and <strong>9d</strong>: (A) Retrosynthetic analysis
of <strong>9c</strong>; (B) Chemical synthesis of <strong>9c</strong> and
analogs <strong>9a</strong>, <strong>9b</strong>, <strong>9d</strong>, and <strong>9e</strong>

.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12332598_ao5c03645_0005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/2ef797cd7c88/ao5c03645_0005.jpg" loading="lazy" id="gr3" height="692" width="796" alt="1"></a></p>
<div class="p text-right font-secondary"><a href="figure/sch1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="sch1-fn1"><sup>a</sup> Reagents and conditions: (i)
conc. HCl, NaNO2, H2O, 0 °C, 1 h; (ii) <strong>3</strong>, NaOAc,
EtOH, 0 °C to rt, overnight, 46%; (iii) ClCH2CN, Et3N, μwave,
120 °C, 1.5 h, 41%; (iv) CH3CH2I, Cs2CO3, DMF, 0 °C to rt,
overnight, 22–38%; (v) NBS, AcOH, μwave, 150 °C,
40 min, 66%; (vi) NCS, AcOH, μwave, 150 °C, 40 min, 96%;
(vii) Selectfluor, ACN, μwave, 150 °C, 4 h, 26%; (viii)
10% aq. KOH, EtOH, reflux, 2 h then 1 N HCl, 33–55%; (ix) <strong>5</strong>, TiCl4, pyridine, reflux, 3 h, 27–55%.</p></figcaption></figure><p>For the synthesis of the second key intermediate <strong>8</strong>, <em>N</em>-1 alkylation of the pyrazole <strong>6b</strong> was initially attempted. However, this reaction produced <strong>7a</strong> in poor yields. Consequently, the methyl ester <strong>6a</strong> was
used as the starting material for alkylation and <strong>7a</strong> was
obtained in improved yields (<a href="#sch1" class="usa-link">Scheme 
</a>B). Bromination of <strong>7a</strong> with NBS under microwave
irradiation gave the ester <strong>7c</strong> in moderate yields, which was then hydrolyzed to obtain the 4-bromo
derivative <strong>8c</strong>.</p>
<p>In the last step to synthesize compound <strong>9c</strong>, amidation
of <strong>5</strong> and <strong>8c</strong> was first performed under EDC/HOBt
conditions, but the results were irreproducible with poor yields (&lt;10%).
Other unsuccessful amidations included reagents such as BCl<sub>3</sub>·(CH<sub>3</sub>)<sub>2</sub>S, BF<sub>3</sub>·O­(C<sub>2</sub>H5)<sub>2</sub> and PPh<sub>3</sub>/COCl<sub>2</sub>. However,
a modified amidation with TiCl<sub>4</sub> improved the reproducibility and yields of <strong>9c</strong> (<a href="#sch1" class="usa-link">Scheme 
</a>B).</p>
<p>Following
our earlier described alkylation and deprotection steps,
intermediate pyrazoles <strong>8a</strong> and <strong>8b</strong> were synthesized
from <strong>6a</strong> or <strong>6b</strong>, respectively, with moderate
yields. Chlorination of <strong>7a</strong> with NCS, followed by ester
deprotection, gave <strong>7d</strong> (<a href="#sch1" class="usa-link">Scheme 
</a>B). On the other hand, fluorination of <strong>7a</strong> using Selectfluor to produce <strong>7e</strong> did not go
to completion. During the reaction, it was a challenge to differentiate
between <strong>7a</strong> and <strong>7e</strong> for monitoring the reaction
progress, thus, after quenching the reaction, the mixture of <strong>7a</strong> and <strong>7e</strong> was carried forward to the next step
without separation, and the mixture of <strong>8a</strong> and <strong>8e</strong> was separated.</p>
<p>Compound <strong>9a</strong> was synthesized from <strong>5</strong> and <strong>8a</strong> using EDC/HOBt conditions to determine
if the size of bromo
moiety in <strong>8c</strong> influenced the yield of amidation. The synthesis
of <strong>9c</strong> was inconsistent through this path and was obtained
in poor yields. Thus, subsequent amidations were performed with TiCl4
to afford analogs <strong>9a</strong>, <strong>9b</strong>, <strong>9d</strong>, and <strong>9e</strong> (<a href="#sch1" class="usa-link">Scheme 
</a>B).</p></section><section id="sec2.1.2"><h4 class="pmc_sec_title">Synthesis of Compounds <strong>19</strong> and <strong>27</strong>
</h4>
<p>Compound <strong>19</strong> could be obtained by
amidation of <strong>17</strong> using the commercially available sulfonyl
chloride <strong>18</strong> (<a href="#sch2" class="usa-link">Scheme 
</a>A). Pyrazole <strong>16</strong> could be formed from ethyl
hydrazine <strong>15</strong> and dicarbonyl <strong>14</strong>. Compound <strong>14</strong> can be obtained by the reduction of ester <strong>13</strong>. Compound <strong>13</strong> can be produced via acylation of Boc-protected
alkyl cuprate <strong>11</strong> and commercially available ethyl malonyl
chloride <strong>12</strong>. However, compound <strong>13</strong> could not be obtained from the alkyl cuprate <strong>11</strong>. However,
Compound <strong>13</strong> was obtained by reacting Boc-protected proline <strong>21</strong>
 with Meldrum’s acid,
EDC, and DMAP, followed by refluxing in EtOH. Subsequent reduction of <strong>13</strong> to aldehyde <strong>14</strong> using DIBAL-H or LiAlH<sub>4</sub>, as well as the formation of
pyrazole from <strong>14</strong> and <strong>15</strong> in an organic base
or protic solvents did not yield compound <strong>16</strong> as conceived
in <a href="#sch2" class="usa-link">Scheme 
</a>A. Several
other approaches were attempted to synthesize compound <strong>16</strong> unsuccessfully, including via pyrazole-5-pinnacol-boronic acid,
Pd-catalyzed [(Pd­(PPh<sub>3</sub>)<sub>4,</sub> XPhosPdG3 or XPhosPdG4]
Suzuki-Miyaura couplings, one-pot reactions
with 4,4-diethoxybutan-1-amine using Lewis acids and ionic liquids, and lithiations at the 2-position of the protected
pyrrolidine using LDA, <em>n</em>-BuLi, or <em>sec</em>-BuLi.</p>
<figure class="fig xbox font-sm" id="sch2"><h5 class="obj_head">2. (A) Retrosynthetic Analysis for Compound <strong>19</strong>, (B)
Synthesis
of compounds <strong>19</strong> and <strong>27</strong>

.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/ecc1f8a6e207/ao5c03645_0006.jpg" loading="lazy" id="gr4" height="2700" width="3833" alt="2"></p>
<div class="p text-right font-secondary"><a href="figure/sch2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="sch2-fn1"><sup>a</sup> Reagents and conditions: (i)
Boc2O, Et3N, DCM, 0 °C to rt, overnight; 88%; (ii) HON­(OMe)­Me,
EDC·HCl, HOBt·H2O, Et3N, DCM, 0 °C to rt, overnight;
72%; (iii) HCCSiMe3, EtMgBr, THF, 0 °C, to rt, overnight; 58%;
(iv) Et2NH, EtOH 0 °C to rt, overnight; (v) compound <strong>15</strong>, EtOH, reflux, overnight; (vi) TFA/DCM; (1:1), 0 °C to rt,
2 h; 28% (over 3 steps); (vii) <strong>18</strong>, Et3N, DCM 0 °C
to rt, overnight, 4–13%.</p></figcaption></figure><p>Then the synthetic
strategy for compound <strong>19</strong> was modified
and was synthesized according to <a href="#sch2" class="usa-link">Scheme 
</a>B. Proline (<strong>20</strong>) was protected
with <em>t-</em>butyloxycarbamoyl moiety (<em>t</em>-Boc) to yield <strong>21</strong>, which
was then subjected to EDC coupling conditions to give the Weinreb amide <strong>22</strong> in good yields. The reaction
of compound <strong>22</strong> with the ethynyl trimethylsilane/ethylmagnesium
bromide complex produced acetylenic ketone <strong>23</strong>. Compound <strong>23</strong> represents a key intermediate
as the next reaction determines the regioselectivity of 1,3- and 1,5-disubsituted
pyrazoles formation (<a href="#sch2" class="usa-link">Scheme 
</a>B).</p>
<p>Compound <strong>23</strong> can be reacted with hydrazine <strong>15</strong> to obtain compound <strong>25</strong> as the major product,
if the
1,3-disubstituted pyrazole <strong>25</strong> is desired. However, if <strong>23</strong> is reacted with
diethylamine, followed by condensation with <strong>15</strong>, the 1,5-disubstituted
pyrazole <strong>16</strong> would be the major product. Under acidic conditions, the regioselectivity of 1,3-disubstituted
pyrazole is proposed to be governed by the increased competition for
hydrazone formation through the 1,2-addition of the basic nitrogen
of the hydrazine. On the other hand,
the 1,5-disubstituted pyrazole <strong>16</strong> is preferentially formed
in the absence of acid or at an elevated temperature via Michael addition
followed by cyclization. Accordingly, <strong>23</strong> was reacted with diethylamine to form the <em>trans</em>-enamino ketone <strong>24</strong>, and upon condensation with hydrazine <strong>15</strong>, both the 1,5- and 1,3-disubstituted pyrazoles <strong>16</strong> and <strong>25</strong>, respectively, were obtained.</p>
<p>The mixture
of <strong>16</strong> and <strong>25</strong> was subjected
to deprotection to obtain the regioisomeric mixture of <strong>17</strong> and <strong>26</strong>. This mixture was subjected to amidation with
the sulfonyl chloride <strong>18</strong>, followed by HPLC separation,
to obtain compounds <strong>19</strong> and <strong>27</strong> as pure compounds.
These compounds provided the opportunity to evaluate the importance
of 1,3- vs 1,5-regiochemistry for biological activity.</p></section><section id="sec2.1.3"><h4 class="pmc_sec_title">Synthesis
of Compounds <strong>33</strong> and <strong>34</strong>
</h4>
<p>The synthesis
of compounds <strong>33</strong> and <strong>34</strong> is
presented in <a href="#sch3" class="usa-link">Scheme 
</a>. The Knorr pyrazole reaction of phenylhydrazine <strong>28</strong> and
the commercially available thiophene <strong>29</strong> in EtOH afforded
compound <strong>30</strong> in moderate yields using conventional heating.
This reaction was also performed under microwave irradiation (150
°C for 0.5 h) in EtOH or toluene, but the yields were lower. Hydrolysis of the ethyl ester <strong>30</strong>, followed by amidation with <strong>32</strong> gave compound <strong>33</strong> in good yields. Further hydrolysis
of ethyl ester <strong>33</strong> gave compound <strong>34</strong> in good
yields.</p>
<figure class="fig xbox font-sm" id="sch3"><h5 class="obj_head">3. Synthesis of Compounds <strong>33</strong> and <strong>34</strong>

.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/e58227ade884/ao5c03645_0007.jpg" loading="lazy" id="gr5" height="992" width="4167" alt="3"></p>
<div class="p text-right font-secondary"><a href="figure/sch3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="sch3-fn1"><sup>a</sup> Reagents and conditions: (i)
EtOH, 70 °C, overnight, 68% (ii) 10% KOH (aq), EtOH reflux, 2
h then 1 N HCl; (iii) <strong>32</strong>, EDC·HCl, HOBt·H<sub>2</sub>O, DIPEA, DCM, 0 °C to rt, overnight, 85% over 2 steps;
(iv) 10% KOH (aq), EtOH reflux, 2 h then 1 N HCl, 88%.</p></figcaption></figure></section><section id="sec2.1.4"><h4 class="pmc_sec_title">Synthesis of Compound <strong>41</strong>
</h4>
<p>Compound <strong>41</strong> was synthesized in four steps (<a href="#sch4" class="usa-link">Scheme 
</a>). First, the Knorr-pyrazole synthesis of
phenylhydrazine <strong>28</strong> and cyanoacetate <strong>35</strong> was
conducted under microwave irradiation in toluene or EtOH to give 5-aminophenypyrazole <strong>36</strong>. Then, following a Clauson-Kass
reaction of 5-aminophenypyrazole <strong>36</strong> and the furan <strong>37</strong>, compound <strong>38</strong> was obtained. Hydrolysis of the ethyl ester <strong>38</strong> provided
the carboxylate <strong>39</strong>. Subsequently, the final amidation
step was performed with EDC/HOBt coupling of <strong>39</strong> and the
thiazole <strong>40</strong> to obtain compound <strong>41</strong>.</p>
<figure class="fig xbox font-sm" id="sch4"><h5 class="obj_head">4. Synthesis
of Compound <strong>41</strong>

.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/f123f5697f90/ao5c03645_0008.jpg" loading="lazy" id="gr6" height="800" width="3492" alt="4"></p>
<div class="p text-right font-secondary"><a href="figure/sch4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="sch4-fn1"><sup>a</sup> Reagents and conditions:
(i) <strong>35</strong>, toluene, μwave, 120 °C, 1 h (ii) <strong>37</strong>, AcOH, reflux, 3 h; 57% over two steps (iii) 10% KOH (aq),
EtOH,
reflux, 2 h then 1 N HCl (iv) <strong>40</strong>, EDC·HCl, HOBt·H<sub>2</sub>O, DIPEA, DCM, 0 °C to rt, overnight; 18% over two steps.</p></figcaption></figure></section></section><section id="sec2.2"><h3 class="pmc_sec_title">Biology: In Vitro Evaluations</h3>
<p>Compounds <strong>9c</strong>, <strong>19</strong>, <strong>33</strong>, and <strong>41</strong> were
synthesized
independently, as their earlier activities were evaluated using commercially
purchased samples. These compounds were re-evaluated in vitro to compare
with the chemical library-derived data. These compounds contain the
pyrazole core structure, which seem to be a key component in driving
desirable activities in the biological assays. Compounds <strong>5</strong>, <strong>9a</strong>–<strong>9e</strong>, <strong>19</strong>, <strong>27</strong>, <strong>33</strong>, <strong>34</strong>, and <strong>41</strong> were
evaluated in the MMA to determine the inhibition of phagocytosis of
opsonized RBCs with anti-D by human monocytes, and the corresponding
dose–response profiles are shown in <a href="#fig1" class="usa-link">Figure 
</a> and <a href="#tbl1" class="usa-link">Table 
</a>.</p>
<figure class="fig xbox font-sm" id="fig1"><h4 class="obj_head">1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/96fa0b2a8e3e/ao5c03645_0003.jpg" loading="lazy" id="gr7" height="262" width="611" alt="1"></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Dose–response profiles for the inhibition of phagocytosis
of the resynthesized hit compounds (<strong>9c</strong>, <strong>19</strong>, <strong>33</strong>, and <strong>41</strong>) and newly synthesized analogs
(<strong>5</strong>, <strong>9a</strong>, <strong>9b</strong>, and <strong>34</strong>). Results are shown only for compounds with IC<sub>50</sub> values
&lt;100 μM. Data points are represented as mean (<em>n</em> = 3) ± SD. IC<sub>50</sub> values were derived using a dose–response
inhibition equation with variable slope.</p></figcaption></figure><section class="tw xbox font-sm" id="tbl1"><h4 class="obj_head">1. Phagocytosis Index (PI), Percent Inhibition
and IC<sub>50</sub> of the Re-Synthesized Hit Compounds (<strong>9c</strong>, <strong>19</strong>, <strong>33</strong>, and <strong>41</strong>) and Newly
Synthesized Analogs (<strong>5</strong>, <strong>9a</strong>, <strong>9b</strong>, <strong>9d</strong>, <strong>9e</strong>, <strong>27</strong>, and <strong>34</strong>)­<sup></sup>
.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="±" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="center" colspan="1" rowspan="1">compound</th>
<th align="center" colspan="1" rowspan="1">PI<sup></sup> ± SD</th>
<th align="center" colspan="1" rowspan="1">inhibition (%) ±
SD</th>
<th align="center" colspan="1" rowspan="1">IC50 (μM) ± std. error</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>5</strong>
</td>
<td align="center" colspan="1" rowspan="1">40 ±
7</td>
<td align="left" colspan="1" rowspan="1">37.1 ± 5.5</td>
<td align="left" colspan="1" rowspan="1">53.3 ± 17.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>9a</strong>
</td>
<td align="center" colspan="1" rowspan="1">75 ± 5</td>
<td align="left" colspan="1" rowspan="1">1.1 ± 1.7</td>
<td align="left" colspan="1" rowspan="1">48.1 ± 6.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>9b</strong>
</td>
<td align="center" colspan="1" rowspan="1">53 ± 2</td>
<td align="left" colspan="1" rowspan="1">30.0
± 6.7</td>
<td align="left" colspan="1" rowspan="1">37.3 ± 6.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>9c</strong>
<sup></sup>
</td>
<td align="center" colspan="1" rowspan="1">43 ±
4</td>
<td align="left" colspan="1" rowspan="1">41.0 ± 6.3 (80 ± 3.68)</td>
<td align="left" colspan="1" rowspan="1">17.7 ± 3.4 (2.7 ± 0.8)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>9d</strong>
</td>
<td align="center" colspan="1" rowspan="1">75 ±
6</td>
<td align="left" colspan="1" rowspan="1">&lt;0.5</td>
<td align="left" colspan="1" rowspan="1">&gt;100</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>9e</strong>
</td>
<td align="center" colspan="1" rowspan="1">80 ± 3</td>
<td align="left" colspan="1" rowspan="1">&lt;0.5</td>
<td align="left" colspan="1" rowspan="1">&gt;100</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>19</strong>
<sup></sup>
</td>
<td align="center" colspan="1" rowspan="1">42 ± 1</td>
<td align="left" colspan="1" rowspan="1">33.3 ± 6.4 (75
± 4.76)</td>
<td align="left" colspan="1" rowspan="1">25.5 ± 6.7 (&gt;5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>27</strong>
</td>
<td align="center" colspan="1" rowspan="1">85 ± 3</td>
<td align="left" colspan="1" rowspan="1">&lt;0.5</td>
<td align="left" colspan="1" rowspan="1">&gt;100</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>33</strong>
<sup></sup>
</td>
<td align="center" colspan="1" rowspan="1">38 ± 8</td>
<td align="left" colspan="1" rowspan="1">45.2 ± 16.4
(81 ± 3.43)</td>
<td align="left" colspan="1" rowspan="1">12.4 ± 2.7 (4.2 ± 1.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>34</strong>
</td>
<td align="center" colspan="1" rowspan="1">78 ± 3</td>
<td align="left" colspan="1" rowspan="1">14.3 ± 3.0</td>
<td align="left" colspan="1" rowspan="1">76.3 ± 8.6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>41</strong>
<sup></sup>
</td>
<td align="center" colspan="1" rowspan="1">41 ±
6</td>
<td align="left" colspan="1" rowspan="1">42.1 ± 3.9 (69 ± 5.32)</td>
<td align="left" colspan="1" rowspan="1">18.4
± 8.5 (&gt;5)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t1fn1">
<sup>a</sup><p class="display-inline">PI and percent
inhibition results
are for compound screening at 5 μM. Compounds were compared
to the reference compound, intravenous immunoglobulin (IVIG) at 1
mg/mL.</p>
</div>
<div class="fn" id="t1fn2">
<sup>b</sup><p class="display-inline">Phagocytosis Index <span xmlns:mml="http://www.w3.org/1998/Math/MathML">
<math id="d1e1295" display="inline"><mo stretchy="false">(</mo><mi>PI</mi><mo stretchy="false">)</mo><mo>=</mo><mfrac><mrow><mi>#</mi><mspace width="0.25em"></mspace><mi>of</mi><mspace width="0.25em"></mspace><mi>phagocytic</mi><mspace width="0.25em"></mspace><mi>RBCs</mi></mrow><mrow><mn>300</mn><mspace width="0.25em"></mspace><mi>monocytes</mi></mrow></mfrac><mo>×</mo><mn>100</mn></math>
</span>.</p>
</div>
<div class="fn" id="t1fn3">
<sup>c</sup><p class="display-inline">Resynthesized compounds in the laboratory.
Activities in parentheses reflect those of the commercially purchased
compounds as previously reported.
</p>
</div>
</div></section></section><section id="sec2.3"><h3 class="pmc_sec_title">Structure–Activity Relationships</h3>
<p>Within the
dipyrazole compounds <strong>9a</strong>–<strong>e</strong>, including
the precursor <strong>5</strong>, the resynthesized bromo-compound <strong>9c</strong> displayed the best results with the lowest phagocytosis
index (PI), highest percent inhibition of phagocytosis and lowest
IC<sub>50</sub> value of 17.7 ± 3.4 μM, which is at least
2-fold lower than the other compounds. On the other hand, the chloro-
and fluoro- derivatives, <strong>9d</strong> and <strong>9e</strong>, respectively,
showed poor activity in inhibiting phagocytosis of RBCs. Methyl derivative <strong>9b</strong> gave the second-best result, leading to the suggestion
that strong electron withdrawing or donating groups at this position
have trivial effect on the activity. Compound <strong>9c</strong> carrying
the bromo moiety could act promiscuously to give the observed results,
due to its potential chemical reactivity. Additional experiments are
needed to support the potential reactivity of compound <strong>9c</strong>. Generally, compounds with neutral or electron-donating groups in
the 4-position of the pyrazole ring B (<strong>9a</strong> and <strong>9b</strong>) gave better biological activity than compounds with electron-withdrawing
groups (<strong>9d</strong> and <strong>9e</strong>).</p>
<p>The pyrrolidine
derivative <strong>19</strong>, originally identified from the commercial
chemical library, displayed a lower phagocytosis index, a more potent
inhibition, and a lower IC<sub>50</sub> of 25.5 ± 6.7 μM,
compared to its regioisomer <strong>27</strong> which was inactive. This
result may indicate that 1,5-disubstituted compound <strong>19</strong> is sterically more favorable than its 1,3-disubstituted regioisomer <strong>27</strong>. Compound <strong>19</strong> carries a chiral center, but
its racemic mixture was synthesized and tested at this stage. Synthesis
of enantiomerically pure <strong>19</strong> may be a subject of future
investigations. The pyrrole derivative <strong>41</strong> exhibited better
activity than all other compounds except <strong>9c</strong> and <strong>33</strong>, with an IC<sub>50</sub> value of 18.4 ± 8.5 μM.
Of all the tested compounds, the thiophene derivative <strong>33</strong> demonstrated the highest inhibition with an IC<sub>50</sub> of 12.4
± 2.7 μM. This is approximately 7-fold more potent than
its carboxylate analog <strong>34</strong>. Since the only structural
difference between the <strong>33</strong> and <strong>34</strong> is the
presence of the methyl ester in <strong>33</strong>, the presence of this
group and its position may play a significant role in the inhibition
of phagocytosis. However, further investigations are needed to corroborate
this theory.</p>
<p>There are noteworthy differences between the in
vitro results of
the commercially acquired chemical library compounds and the resynthesized
compounds in the laboratory. In vitro, the synthesized compounds displayed
slightly less potent activities and can be partially attributed to
the differences in the level of purity (or impurities). Full characterization
of the commercial compounds was a challenge due to the small quantities
of the compounds, and resynthesized compounds were completely characterized
including purity. These differences highlight the importance of independently
synthesizing and re-evaluating the compounds obtained from commercial
chemical libraries. In the context of the in vitro assays, blood from
ten different human donors was used in the phagocytosis assays, and
it is also highly likely that the differences in the in vitro results
are due to the donor–donor variability.</p>
<p>Despite the above
differences, compounds <strong>9c</strong> and <strong>33</strong> showed
no toxicity, but good potency to inhibit in vitro
FcγR-mediated phagocytosis.<em>
,
</em> However, <strong>9c</strong> may act nonselectively due to the bromo-functionality and
thus was considered unsuitable as a potential candidate for further
investigations. Resynthesized compound <strong>33</strong> exhibited superiority
in comparison with the other resynthesized compounds. Thus, the in
vivo pharmacokinetics properties of compound <strong>33</strong> were
determined (vide infra).</p>
<section id="sec2.3.1"><h4 class="pmc_sec_title">Efficacy of Compound <strong>33</strong>
</h4>
<p>The mechanisms
and potential therapies for human ITP are commonly investigated using
mouse models,<em>
,−

</em> particularly
passive, antibody transfer models of ITP.<em>
,−

</em> This model involves an antibody (clone MWReg30, rat
IgG1:λ) that targets the platelet glycoprotein IIb, a self-antigen
highly relevant to the human ITP.<em>
,,
</em> Twenty four hours after the anti-CD41 injection,
mice experience a significant decrease in platelet count due to immune
system-mediated platelet destruction. Repeated administration of escalating
doses of anti-CD41 antibody leads to prolonged thrombocytopenia that
resembles chronic human ITP.<em>
,
</em> On the other hand,
spontaneous platelet recovery also can occur in the absence of a dose-escalating
regimen.<em>
,
</em> As a result of this antibody dose-escalation
mode, a protracted platelet nadir is observed, likely by influencing
the megakaryocyte compartment and compensatory platelet production
as well as increasing the rate of platelet destruction.<em>
,
</em>
</p>
<p>In a recent report, compound <strong>33</strong> was investigated for its ability to ameliorate the experimental
ITP in vivo in BALB/c mice by using the passive, rat antimouse CD41
antibody transfer. In comparison to untreated mice (CD41), compound <strong>33</strong> at a dose of 2.5 mg/kg in BALB/c mice resulted in an increased
platelet count after the first day of treatment. Additionally, at
1 mg/kg of <strong>33</strong>, a significant increase in platelet concentrations
after the second day was observed.</p>
<p>Molecules such as compound <strong>33</strong> can be a potential treatment
for several immune cytopenias because the in vitro phagocytosis assay
uses antibody-opsonized RBCs, and in vivo testing shows the molecule
is also highly effective at ameliorating ITP and in the recovery of
platelet counts in an animal model.</p></section><section id="sec2.3.2"><h4 class="pmc_sec_title">Pharmacokinetics of <strong>33</strong>
</h4>
<p>A single-dose pharmacokinetic
analyses in healthy female and male BALB/c mice to determine the levels
of compound <strong>33</strong> in the plasma were performed. The animals
received a single dose of compound <strong>33</strong> (1 mg/kg) via IP
injection and blood samples were collected at nine time points over
24 h (<a href="#fig2" class="usa-link">Figure 
</a>). However,
the results obtained by LC–MS for both female and male mice
indicated the rapid conversion of methyl ester <strong>33</strong> and
the formation of ester hydrolysis product <strong>34</strong> in the blood.
Compound <strong>33</strong> was not detected in blood/plasma and no other
metabolites were identified in this experiment.</p>
<figure class="fig xbox font-sm" id="fig2"><h5 class="obj_head">2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/deb8/12332598/bc48dc6a7fe2/ao5c03645_0004.jpg" loading="lazy" id="gr8" height="396" width="555" alt="2"></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Concentration–time
profile for compound <strong>34</strong> in
plasma obtained from healthy female and male BALB/c mice (<em>n</em> = 3 per time point) after a single dose of <strong>33</strong> (1 mg/kg, <em>i.p.</em>), monitored for up to 24 h postadministration.
The concentration of <strong>34</strong> in female and male plasma was
derived from standard curves.</p></figcaption></figure><p>The exposure to <strong>34</strong> during 24 h (AUC<sub>(0–24)</sub>) was slightly higher in male mice (1.218 ± 0.1912 h*μg/mL),
than that in females (0.9397 ± 0.1235 h*μg/mL). Differences
in pharmacokinetics in males and females are quite interesting, and
future studies need to explore this further.</p>
<p>
<a href="#tbl2" class="usa-link">Table 
</a> shows the
pharmacokinetics profile of compound <strong>34</strong> in healthy female
and male BALB/c mice. The maximum concentration (<em>C</em>
<sub>max</sub>) of <strong>34</strong>, was higher in the female mice
than in males (0.44 and 0.14 μg/mL, respectively). In female
mice, the time to reach <em>C</em>
<sub>max</sub> (<em>T</em>
<sub>max</sub>) was observed at 15 min after administration,
in comparison to 30 min in males. The elimination of compound <strong>34</strong> was faster in female mice than male mice, as evidenced
by their respective elimination constants (<em>k</em>
<sub>el</sub>) of 0.33 and 0.096 h<sup>–1</sup> (<a href="#tbl2" class="usa-link">Table 
</a>). The half-life (<em>t</em>
<sub>1/2</sub>) of <strong>34</strong> in female mice was shorter than
males, with values of 2.12 and 7.24 h, respectively.</p>
<section class="tw xbox font-sm" id="tbl2"><h5 class="obj_head">2. Pharmacokinetics Profile of Compound <strong>34</strong> after the Administration
of <strong>33</strong> in Plasma from
Healthy Female and Male BALB/c Mice (<em>n</em> = 27 Each)<sup></sup>
.</h5>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
</colgroup>
<thead><tr>
<th align="center" colspan="1" rowspan="1">parameter</th>
<th align="center" colspan="1" rowspan="1">female</th>
<th align="center" colspan="1" rowspan="1">male</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<em>C</em><sub>max</sub> (μg/mL)</td>
<td align="left" colspan="1" rowspan="1">0.44</td>
<td align="left" colspan="1" rowspan="1">0.14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<em>T</em><sub>max</sub> (h)</td>
<td align="left" colspan="1" rowspan="1">0.25</td>
<td align="left" colspan="1" rowspan="1">0.50</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<em>k</em><sub>el</sub> (h<sup>–1</sup>)</td>
<td align="left" colspan="1" rowspan="1">0.33</td>
<td align="left" colspan="1" rowspan="1">0.096</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<em>t</em><sub>1/2</sub> (h)</td>
<td align="left" colspan="1" rowspan="1">2.12</td>
<td align="left" colspan="1" rowspan="1">7.24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AUC<sub>0–24</sub> (h*μg/mL)</td>
<td align="left" colspan="1" rowspan="1">0.9397 ± 0.1235</td>
<td align="left" colspan="1" rowspan="1">1.218 ± 0.1912</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="t2fn1">
<sup>a</sup><p class="display-inline">The exposure to compound <strong>34</strong> in the systemic circulation
was determined as AUC by integrating
the plasma concentration versus time curves. <em>C</em>
<sub>max</sub> and <em>T</em>
<sub>max</sub> were determined from
the concentration vs time curves. The half-life (<em>t</em>
<sub>1/2</sub>) for the drug elimination was calculated using the
formula <em>t</em>
<sub>1/2</sub> = 0.693/<em>k</em>
<sub>el</sub>.</p>
</div></div></section></section></section></section><section id="sec3"><h2 class="pmc_sec_title">Conclusions</h2>
<p>Here, we describe the synthesis and subsequent in vitro evaluation
of the four hit compounds and their analogs. The resynthesized hit
molecules <strong>9c</strong>, <strong>19</strong>, <strong>33</strong>, and <strong>41</strong> appear to be slightly less potent than the commercially
acquired library molecules, buttressing the need to revalidate hit
molecules and their purities when testing compounds. The analogs of
these hit molecules were either equal or less potent as inhibitors
of phagocytosis, compared to the resynthesized hit compounds. Generally,
compounds with neutral or electron-donating groups in the 4-position
of the pyrazole ring B (<strong>9a</strong> and <strong>9b</strong>) gave
better activity in vitro than compounds with electron-withdrawing
groups (<strong>9d</strong> and <strong>9e</strong>), among the dipyrazole
derivatives. It is also observed that 1,3-substituion on the pyrazole
moiety is not favored, but 1,5- and 1,3,5-substitutions are favored.
Of all the compounds, <strong>33</strong> consistently demonstrated the
best percent inhibition and dose response in in vitro phagocytosis
assays, and good efficacy in in vivo mouse models of ITP.</p>
<p>Compounds <strong>33</strong> and <strong>34</strong> differ only by the
presence of a methyl ester moiety, but there was approximately 7-fold
difference in their in vitro activity. The presence of the methyl
ester in <strong>33</strong> may be important, although further investigations
are needed to corroborate this observation.</p></section><section id="sec4"><h2 class="pmc_sec_title">Experimental Section</h2>
<section id="sec4.1"><h3 class="pmc_sec_title">Chemistry</h3>
<section id="sec4.1.1"><h4 class="pmc_sec_title">General</h4>
<p>All anhydrous reactions were performed under
nitrogen atmosphere and anhydrous solvents were prepared following
standard procedures. Compounds <strong>1</strong>, <strong>6a</strong>, <strong>6b, 15, 18, 20</strong>, <strong>29</strong>, <strong>32</strong>, <strong>35</strong>, <strong>37</strong>, <strong>40</strong>, reagents, and solvents were obtained
from commercial sources. Reaction progress was monitored on thin layer
chromatography (TLC) plates (Silica gel-60 F<sub>254</sub>). Chromatographic
purifications were performed using silica gel (60 Å; 70–230
or 325–625 mesh) or Biotage flash chromatography system with
Silicycle prepacked silica gel columns. Microwave irradiations were
performed using a Biotage Initiator microwave (2.45 GHz, 400 W). Sonication
was performed by a VWR or Fisher ultrasonic bath with 80W of ultrasonic
power, 63W of heater power, and 40 kHz of operating frequency. NMR
spectra were recorded on a Bruker Avance spectrometer (400.27 MHz
for <sup>1</sup>H, 100.64 MHz for <sup>13</sup>C and 376.62 MHz for <sup>19</sup>F). Chemical shifts were reported in δ ppm using deuterated
chloroform or methanol as a reference.</p>
<p>The purity of the compounds
(two solvent systems; <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.5c03645/suppl_file/ao5c03645_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Supplementary data Table S1 and Figures S33–S44</a>) was determined by tandem HPLC-PDA-MS
equipped with a Waters 2545 binary gradient module, Waters PDA 2998
photodiode array detector (190–800 nm), and a Waters QDa mass
spectrometer (200–1200 Da). HPLC was performed on an X-Bridge
analytical C<sub>18</sub> column (4.6 mm × 150 mm, 5 μm
I.D.). Mass spectra were recorded using ESI (+ve) mode (200–800
Da). All HPLC solvents were HPLC grade. The purity methods used for
analysis are described further below. All but three compounds evaluated
in vitro are ≥95% pure by HPLC analysis. Compounds <strong>9a</strong> and <strong>9b</strong> are &lt;95% pure in both solvent systems, while <strong>9e</strong> is &lt;95% pure in one solvent system (Method 2). Since
these compounds did not display promising IC<sub>50</sub> results
and will not be evaluated further, no additional attempts at increasing
the purity were made.</p></section><section id="sec4.1.2"><h4 class="pmc_sec_title">Synthesis</h4>
<section id="sec4.1.2.1"><h5 class="pmc_sec_title">Ethyl (<em>E</em>)-2-cyano-2-(2-phenylhydrazineylidene)
acetate (<strong>4</strong>)</h5>
<p>To aniline <strong>1</strong> (0.78
mL, 8.59 mmol) suspended in a conc. HCl (1.43 mL, 17.18 mmol) at 0
°C, sodium nitrite (0.59 g, 8.59 mmol) in water (1.5 mL) was
added dropwise. The mixture was stirred at 0 °C for 1 h, and
ethyl 2-cyanoacetate (0.91 mL, 8.59 mmol) in EtOH (1.5 mL), followed
by sodium acetate (1.41 g, 17.18 mmol), was added. The reaction mixture
was then stirred at rt overnight, concentrated in vacuo, and the crude
was purified by Biotage using 0–5% EtOAc in hexanes to afford <strong>4</strong> (0.86 g, 46%) as an orange solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.35 (s, 1H), 7.43–7.31 (m, 4H), 7.23–7.17
(m, 1H), 4.39 (dq, <em>J</em> = 12.4, 7.1 Hz, 2H), 1.40 (td, <em>J</em> = 7.1, 4.0 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.7, 160.5, 140.9, 140.5, 129.8, 126.2, 125.9, 116.0,
115.9, 115.5, 110.4, 106.1, 62.5, 62.5, 14.4, 14.2. MS (ESI + ve):
calculated [M + H]<sup>+</sup> C<sub>11</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>: 218.09; found 218.09.</p></section><section id="sec4.1.2.2"><h5 class="pmc_sec_title">Ethyl 4-amino-5-cyano-1-phenyl-1H-pyrazole-3-carboxylate
(<strong>5</strong>)</h5>
<p>Compound <strong>4</strong> (0.86 g, 3.94 mmol)
was
suspended in Et<sub>3</sub>N (8 mL) in a microwave vial and sonicated
at 40 °C until a solution was obtained. To this solution was
added chloroacetonitrile (0.10 mL, 15.76 mmol) and the mixture sonicated
again at 40 °C until a solution was obtained. The reaction mixture
was subjected to microwave irradiation at 120 °C for 1.5 h. The
reaction mixture was concentrated in vacuo, and the crude was purified
by Biotage using 0–15% EtOAc in hexanes to afford <strong>5</strong> (0.41 g, 41%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.72–7.67 (m, 2H), 7.53–7.41 (m, 3H), 4.96
(s, 2H), 4.46 (q, <em>J</em> = 7.1 Hz, 2H), 1.42 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ
162.8, 144.1, 138.5, 130.6, 129.7, 129.3, 122.6, 110.8, 100.1, 61.5,
14.5. MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>13</sub>H<sub>13</sub>N<sub>4</sub>O<sub>2</sub>: 257.10; found 257.10.</p></section></section><section id="sec4.1.3"><h4 class="pmc_sec_title">General Procedure for N-1 Pyrazole Alkylation</h4>
<p>To a
suspension of Cs<sub>2</sub>CO<sub>3</sub> (1.5–3.0 equiv)
in anhyd DMF (2 mL/mmol of pyrazole) at 0 °C, was added starting
material (1 equiv), followed by dropwise addition of iodoethane (1.2–2.4
equiv). The reaction was stirred at rt overnight then filtered and
concentrated in vacuo. The reaction mixture was concentrated in vacuo,
and the crude was purified by Biotage using 0–30% EtOAc in
hexanes to afford the title compound.</p>
<section id="sec4.1.3.1"><h5 class="pmc_sec_title">Methyl 1-ethyl-1H-pyrazole-3-carboxylate
(<strong>7a</strong>)</h5>
<p>Prepared according to the general procedure
outlined above using
Cs<sub>2</sub>CO<sub>3</sub> (7.75 g, 23.79 mmol), <strong>6a</strong> (2.00 g, 15.86 mmol), and iodoethane (1.53 mL, 19.03 mmol). Title
compound <strong>7a</strong> was obtained as a colorless viscous liquid
(0.92 g, 38%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.41 (d, <em>J</em> = 2.4 Hz, 2H), 6.80 (d, <em>J</em> = 2.3 Hz, 1H),
4.25 (q, <em>J</em> = 7.3 Hz, 2H), 3.91 (s, 3H), 1.50 (t, <em>J</em> = 7.4 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ
163.0, 143.2, 129.8, 109.1, 52.1, 48.0, 15.7.</p></section><section id="sec4.1.3.2"><h5 class="pmc_sec_title">Ethyl 1-ethyl-4-methyl-1H-pyrazole-3-carboxylate
(<strong>7b</strong>)</h5>
<p>Prepared according to the general procedure
outlined above
using Cs<sub>2</sub>CO<sub>3</sub> (1.55 g, 4.76 mmol), <strong>6b</strong> (0.20 g, 1.59 mmol), and iodoethane (0.31 mL, 3.81 mmol). Title
compound <strong>7b</strong> was obtained as an off-white solid (63 mg,
22%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.22 (s, 1H), 4.39
(q, <em>J</em> = 7.1 Hz, 2H), 4.19 (q, <em>J</em> =
7.3 Hz, 2H), 2.28 (s, 3H), 1.47 (t, <em>J</em> = 7.3 Hz, 3H),
1.42–1.37 (m, 3H).</p></section></section><section id="sec4.1.4"><h4 class="pmc_sec_title">General Procedure for C-4
Pyrazole Halogenation</h4>
<p>Starting
material (1 equiv) was dissolved in acetic acid (2.4–3.1 mL/mmol
of pyrazole) in a microwave vial, and halogenating agent (1.2 equiv)
was added. The reaction mixture was subjected to microwave irradiation
at 150 °C for 40–60 min. The reaction mixture was concentrated
in vacuo and the crude product was purified by silica gel chromatography
to afford the title compound.</p>
<section id="sec4.1.4.1"><h5 class="pmc_sec_title">Methyl 4-bromo-1-ethyl-1H-pyrazole-3-carboxylate
(<strong>7c</strong>)</h5>
<p>Prepared according to the general procedure
outlined above
using <strong>6a</strong> (0.38 g, 2.48 mmol), acetic acid (6 mL), and
NBS (0.53 g, 2.98 mmol), with microwave irradiation at 150 °C
for 40 min. Silica gel chromatography using 0–20% EtOAc in
hexanes afforded the title compound <strong>7c</strong> as a brown viscous
liquid (0.38 g, 66%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ
7.50 (s, 1H), 4.23 (q, <em>J</em> = 7.3 Hz, 2H), 3.93 (s,
3H), 1.50 (t, <em>J</em> = 7.3 Hz, 3H). MS (ESI + ve): calculated
[M-Me+H]<sup>+</sup> C<sub>6</sub>H<sub>8</sub>BrN<sub>2</sub>O<sub>2</sub>: 218.98; found 218.98.</p></section><section id="sec4.1.4.2"><h5 class="pmc_sec_title">Methyl 4-chloro-1-ethyl-1H-pyrazole-3-carboxylate
(<strong>7d</strong>)</h5>
<p>Prepared according to the general procedure
outlined above
using <strong>7a</strong> (75 mg, 0.49 mmol), acetic acid (1.5 mL), and
NCS (78 mg, 0.58 mmol), with microwave irradiation at 150 °C
for 1 h. Silica gel chromatography using 0–35% EtOAc in hexanes
afforded the title compound <strong>7d</strong> as a colorless viscous
liquid (88 mg, 96%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ
7.47 (s, 1H), 4.21 (q, <em>J</em> = 7.3 Hz, 2H), 3.93 (s,
3H), 1.50 (t, <em>J</em> = 7.4 Hz, 3H).</p></section><section id="sec4.1.4.3"><h5 class="pmc_sec_title">Methyl
1-ethyl-4-fluoro-1H-pyrazole-3-carboxylate (<strong>7e</strong>)</h5>
<p>Compound <strong>7a</strong> (97 mg, 0.63 mmol) and Selectfluor
(0.89 g, 2.52 mmol) were dissolved in acetonitrile (2 mL). The reaction
mixture was subjected to microwave irradiation at 120 °C for
4 h. The reaction mixture was concentrated in vacuo, suspended in
water, and extracted with DCM. The organic layers were combined, dried
over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo.
The crude product was purified by silica gel chromatography using
0–20% EtOAc in hexanes to afford <strong>7e</strong> as a colorless
viscous liquid with a mixture of the starting material (31 mg with
89% purity) and product (28 mg, 26%) <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.34 (d, <em>J</em> = 4.9 Hz, 1H), 4.17 (q, <em>J</em> = 7.4 Hz, 2H), 3.93 (s, 3H), 1.48 (t, <em>J</em> = 7.4 Hz, 3H). <sup>19</sup>F NMR (CDCl3) δ −166.4.</p></section></section><section id="sec4.1.5"><h4 class="pmc_sec_title">General Procedure for Ester Deprotection</h4>
<p>The starting
material (1 equiv) was dissolved in EtOH (3.33 mL/mmol of carboxylate),
and 10% aq. KOH (1.67 mL/mmol of carboxylate) was added. The mixture
was refluxed for 2 h and then cooled to rt. Following acidification
with 1 N HCl, the mixture was concentrated in vacuo. The crude was
purified by silica gel pad using 10% MeOH in DCM to afford the title
compound.</p>
<section id="sec4.1.5.1"><h5 class="pmc_sec_title">1-Ethyl-1H-pyrazole-3-carboxylic acid (<strong>8a</strong>)</h5>
<p>Prepared according to the general procedure outlined above using <strong>7a</strong> (46 mg, 0.30 mmol). Title compound <strong>8a</strong> was
obtained as a white solid (14 mg, 33%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.45 (d, <em>J</em> = 2.3 Hz, 1H), 6.87
(d, <em>J</em> = 2.3 Hz, 1H), 4.28 (q, <em>J</em> =
7.3 Hz, 2H), 1.53 (t, <em>J</em> = 7.3 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 165.9, 142.6, 130.3, 109.6, 48.2,
15.6.</p></section><section id="sec4.1.5.2"><h5 class="pmc_sec_title">1-Ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (<strong>8b</strong>)</h5>
<p>Prepared according to the general procedure outlined above
using <strong>7b</strong> (56 mg, 0.31 mmol). Title compound <strong>8b</strong> was obtained as an off-white solid (24 mg, 55%). <sup>1</sup>H NMR
(CDCl<sub>3</sub>) δ 6.83 (s, 1H), 3.80 (q, <em>J</em> = 7.3 Hz, 2H), 1.95 (s, 3H), 1.12 (t, <em>J</em> = 7.3 Hz,
3H).</p></section><section id="sec4.1.5.3"><h5 class="pmc_sec_title">4-Bromo-1-ethyl-1H-pyrazole-3-carboxylic acid (<strong>8c</strong>)</h5>
<p>Prepared according to the general procedure outlined above
using <strong>7c</strong> (0.13 g, 0.54 mmol). Title compound <strong>8c</strong> was obtained as a brown solid (54 mg, 46%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.53 (s, 1H), 4.25 (q, <em>J</em> = 7.3
Hz, 2H), 1.53 (t, <em>J</em> = 7.4 Hz, 3H). <sup>13</sup>C
NMR (CDCl<sub>3</sub>) δ 163.9, 139.4, 131.9, 97.0, 48.9, 15.4.
MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>6</sub>H<sub>8</sub>BrN<sub>2</sub>O<sub>2</sub>: 218.98; found 218.98.</p></section><section id="sec4.1.5.4"><h5 class="pmc_sec_title">4-Chloro-1-ethyl-1H-pyrazole-3-carboxylic
acid (<strong>8d</strong>)</h5>
<p>Prepared according to the general
procedure outlined above
using <strong>7d</strong> (88 mg, 0.47 mmol). Title compound <strong>8d</strong> was obtained as a white solid (37 mg, 45%). <sup>1</sup>H NMR (MeOD-<em>d</em>
<sub>4</sub>) δ 7.86 (s, 1H), 4.20 (s, 2H), 1.46
(s, 3H).</p></section><section id="sec4.1.5.5"><h5 class="pmc_sec_title">1-Ethyl-4-fluoro-1H-pyrazole-3-carboxylic
acid (<strong>8e</strong>)</h5>
<p>Prepared according to the general
procedure outlined above
using <strong>7e</strong> (28 mg, 0.16 mmol). Title compound <strong>8e</strong> was obtained as a white solid (12 mg, 45%). <sup>1</sup>H NMR (MeOD-<em>d</em>
<sub>4</sub>) δ 7.61 (d, <em>J</em> = 4.7
Hz, 1H), 4.11 (q, <em>J</em> = 7.3 Hz, 2H), 1.43 (t, <em>J</em> = 7.3 Hz, 3H).</p></section></section><section id="sec4.1.6"><h4 class="pmc_sec_title">General Procedure for Amidation</h4>
<p>Phenylpyrazole (1 equiv)
and pyrazole (1 equiv) were dissolved in anhyd pyridine (25.6 mL/mmol
of phenylpyrazole), then TiCl<sub>4</sub> (12 equiv) was added, and
the reaction mixture was refluxed for 3 h. The reaction mixture was
concentrated in vacuo, then quenched with Rochelle’s salt,
diluted with EtOAc, and stirred for 1 h. The reaction mixture was
extracted with EtOAc, and the organic layers were collected. The aqueous
layer was diluted with acetonitrile and filtered. The filtrate was
collected and concentrated in vacuo. The residue was dissolved in
EtOAc, combined with the previously collected EtOAc extract, dried
over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo.
The crude product was purified by Biotage using 0–50% EtOAc
in hexanes to afford the title compound.</p>
<section id="sec4.1.6.1"><h5 class="pmc_sec_title">Ethyl 5-Cyano-4-(1-ethyl-1H-pyrazole-3-carboxamido)-1-phenyl-1H-pyrazole-3-carboxylate
(<strong>9a</strong>)</h5>
<p>Prepared according to the general procedure
outlined above using <strong>5</strong> (10 mg, 0.04 mmol), <strong>8a</strong> (6 mg, 0.04 mmol) and TiCl<sub>4</sub> (0.05 mL, 0.47 mmol). Compound <strong>9a</strong> was obtained as a white solid (4 mg, 27%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.49 (s, 1H), 7.75–7.71
(m, 2H), 7.57–7.48 (m, 3H), 7.47 (d, <em>J</em> = 2.4
Hz, 1H), 6.97 (d, <em>J</em> = 2.3 Hz, 1H), 4.54 (q, <em>J</em> = 7.1 Hz, 2H), 4.28 (q, <em>J</em> = 7.3 Hz, 2H),
1.57 (t, <em>J</em> = 7.3 Hz, 3H), 1.48 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.43,
159.58, 144.89, 138.4, 132.9, 130.7, 130.1, 130.0, 129.6, 124.6, 110.8,
108.3, 108.0, 62.2, 48.0, 29.8, 15.6, 14.5. MS (ESI + ve): calculated
[M + H]<sup>+</sup> C<sub>19</sub>H<sub>19</sub>N<sub>6</sub>O<sub>3</sub>: 379.15; found 379.15.</p></section><section id="sec4.1.6.2"><h5 class="pmc_sec_title">Ethyl 5-Cyano-4-(1-ethyl-4-methyl-1H-pyrazole-3-carboxamido)-1-phenyl-1H-pyrazole-3-carboxylate
(<strong>9b</strong>)</h5>
<p>Prepared according to the general procedure
outlined above using <strong>5</strong> (10 mg, 0.04 mmol), <strong>8b</strong> (7 mg, 0.04 mmol) and TiCl<sub>4</sub> (0.05 mL, 0.47 mmol). Title
compound <strong>9b</strong> was obtained as a white solid (5 mg, 33%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.44 (s, 1H), 7.75–7.71
(m, 2H), 7.57–7.47 (m, 3H), 4.53 (q, <em>J</em> = 7.2
Hz, 2H), 4.20 (q, <em>J</em> = 7.3 Hz, 2H), 2.39 (d, <em>J</em> = 0.8 Hz, 3H), 1.54 (t, <em>J</em> = 7.3 Hz, 3H),
1.47 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 160.4, 141.4, 138.4, 133.0, 130.3, 130.0, 129.9,
129.6, 124.5, 120.7, 110.8, 108.1, 62.1, 47.8, 15.6, 14.5, 9.7. MS
(ESI + ve): calculated [M + H]<sup>+</sup> C<sub>20</sub>H<sub>21</sub>N<sub>6</sub>O<sub>3</sub>: 393.17; found 393.17.</p></section><section id="sec4.1.6.3"><h5 class="pmc_sec_title">Ethyl 4-(4-Bromo-1-ethyl-1H-pyrazole-3-carboxamido)-5-cyano-1-phenyl-1H-pyrazole-3-carboxylate
(<strong>9c</strong>)</h5>
<p>Prepared according to the general procedure
outlined above using <strong>5</strong> (19 mg, 0.07 mmol), <strong>8c</strong> (16 mg, 0.07 mmol) and TiCl<sub>4</sub> (0.10 mL, 0.83 mmol). Title
compound <strong>9c</strong> was obtained as a pale-yellow solid (18 mg,
55%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ <sup>1</sup>H NMR
(400 MHz, CDCl<sub>3</sub>) δ 10.40 (s, 1H), 7.75–7.70
(m, 2H), 7.57–7.48 (m, 4H), 4.52 (q, <em>J</em> = 7.1
Hz, 2H), 4.26 (q, <em>J</em> = 7.3 Hz, 2H), 1.56 (t, <em>J</em> = 7.4 Hz, 3H), 1.46 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.5, 158.2, 140.7, 138.3,
132.1, 130.011, 129.9, 129.7, 124.5, 110.435, 95.7, 62.2, 48.7, 15.3,
14.5. MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>19</sub>H<sub>18</sub>BrN<sub>6</sub>O<sub>3</sub>: 457.06; found 457.06.</p></section><section id="sec4.1.6.4"><h5 class="pmc_sec_title">Ethyl 4-(4-Chloro-1-ethyl-1H-pyrazole-3-carboxamido)-5-cyano-1-phenyl-1H-pyrazole-3-carboxylate
(<strong>9d</strong>)</h5>
<p>Prepared according to the general procedure
outlined above using <strong>5</strong> (10 mg, 0.04 mmol), <strong>8d</strong> (7 mg, 0.04 mmol), and TiCl<sub>4</sub> (0.05 mL, 0.47 mmol). Title
compound <strong>9d</strong> was obtained as a yellow solid (5 mg, 31%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ <sup>1</sup>H NMR (400 MHz,
CDCl<sub>3</sub>) δ 10.40 (s, 1H), 7.75–7.68 (m, 2H),
7.58–7.46 (m, 4H), 4.52 (q, <em>J</em> = 7.1 Hz, 2H),
4.24 (q, <em>J</em> = 7.4 Hz, 2H), 1.56 (t, <em>J</em> = 7.3 Hz, 3H), 1.46 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.5, 158.0, 139.3, 138.3, 130.0,
129.8, 129.7, 129.7, 112.7, 110.5, 108.5, 62.2, 48.7, 15.3, 14.5.
MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>19</sub>H<sub>18</sub>ClN<sub>6</sub>O<sub>3</sub>: 413.11; found 413.11.</p></section><section id="sec4.1.6.5"><h5 class="pmc_sec_title">Ethyl
5-Cyano-4-(1-ethyl-4-fluoro-1H-pyrazole-3-carboxamido)-1-phenyl-1H-pyrazole-3-carboxylate
(<strong>9e</strong>)</h5>
<p>Prepared according to the general procedure
outlined above using <strong>5</strong> (10 mg, 0.04 mmol), <strong>8e</strong> (6 mg, 0.04 mmol), and TiCl<sub>4</sub> (0.05 mL, 0.47 mmol). Title
compound <strong>9e</strong> was obtained as a pale-yellow solid (4 mg,
27%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) 10.31 (s, 1H), 7.75–7.68
(m, 2H), 7.59–7.47 (m, 3H), 7.40 (d, <em>J</em> = 4.7
Hz, 1H), 4.53 (q, <em>J</em> = 7.1 Hz, 2H), 4.21 (q, <em>J</em> = 7.4 Hz, 2H), 1.55 (t, <em>J</em> = 7.4 Hz, 3H),
1.47 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.5, 157.7, 157.7, 150.5, 148.0, 138.3, 132.9,
130.4, 130.4, 130.1, 129.7, 129.7, 124.5, 117.4, 117.1, 110.5, 108.5,
62.3, 49.1, 15.3, 14.5. <sup>19</sup>F NMR (CDCl<sub>3</sub>) δ
−166.9. MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>19</sub>H<sub>18</sub>FN<sub>6</sub>O<sub>3</sub>: 397.14; found
397.14.</p></section><section id="sec4.1.6.6"><h5 class="pmc_sec_title">(tert-Butoxycarbonyl)­proline (<strong>21</strong>)</h5>
<p>Compound <strong>20</strong> (0.50 g, 4.34 mmol) was suspended
in anhyd. DCM (15 mL),
and Et<sub>3</sub>N (0.8 mL, 5.74 mmol) was added. The reaction mixture
was cooled to 0 °C. Boc<sub>2</sub>O (1.42 g, 6.51 mmol) was
added, and the reaction mixture was left stirring overnight at rt.
The reaction mixture was washed with sat. citric acid followed by
washing with sat. brine and water. The organic layer was dried over
Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo.
The crude was purified by silica gel column chromatography using 0–7%
MeOH in DCM to afford <strong>21</strong> as a white solid (0.82 g, 88%)
and a mixture of rotamers. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ
4.25 (ddd, <em>J</em> = 43.5, 8.6, 3.8 Hz, 1H), 3.59–3.29
(m, 2H), 2.24 (dd, <em>J</em> = 20.5, 8.2 Hz, 1H), 2.13–1.76
(m, 3H), 1.45 (s, 5H), 1.40 (s, 4H).</p></section><section id="sec4.1.6.7"><h5 class="pmc_sec_title">
<em>tert</em>-Butyl
2-(Methoxy­(methyl)­carbamoyl)­pyrrolidine-1-carboxylate
(<strong>22</strong>)</h5>
<p>Compound <strong>21</strong> (0.42 g, 1.95
mmol) and Et<sub>3</sub>N (0.82 mL, 5.85 mmol) were dissolved in anhyd.
DCM (8 mL), and the reaction mixture was cooled to 0 °C. EDC·HCl
(0.56 g, 2.93 mmol), and HOBt·H<sub>2</sub>O (0.49 g, 2.93 mmol)
were added, and the reaction was left stirring for 10 min at 0 °C. <em>N,O</em>-Dimethylhydroxylamine·HCl (0.23 g, 2.34 mmol) was
then added, and the reaction was left stirring overnight at rt. The
reaction mixture was diluted with DCM, then washed with water. The
organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered,
and concentrated in vacuo. The crude was purified by silica gel column
chromatography using 0–50% EtOAc in hexanes to afford <strong>22</strong> as a colorless viscous liquid (0.36 g, 72%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) (2:1 mixture of rotamers) δ 4.63 (ddd, <em>J</em> = 41.7, 8.6, 3.5 Hz, 1H), 4.26 (ddd, <em>J</em> = 46.7, 8.6, 3.6 Hz, 0.5H), 3.73 (d, <em>J</em> = 24.2 Hz,
3H), 3.60–3.49 (m, 1H), 3.48–3.28 (m, 2H), 3.17 (s,
3H), 2.29–2.08 (m, 1.5H), 2.07–1.75 (m, 4.5H), 1.47–1.41
(m, 7H), 1.40–1.36 (m, 7H). MS (ESI + ve): calculated [M +
Na]<sup>+</sup> C<sub>12</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>Na: 281.15; found 281.15.</p></section><section id="sec4.1.6.8"><h5 class="pmc_sec_title">
<em>tert</em>-Butyl
2-(3-(Trimethylsilyl)­propioloyl)­pyrrolidine-1-carboxylate
(<strong>23</strong>)</h5>
<p>Ethynyltrimethylsilane (2.65 mL, 18.58
mmol) was dissolved in anhyd. THF (3 mL) at 0 °C, and 3 M ethylmagnesium
bromide (6.19 mL, 18.58 mmol) was added. The reaction mixture was
stirred at 0 °C for 10 min, then at rt for 1 h. The reaction
mixture was cooled to 0 °C, then compound <strong>22</strong> (0.24
g, 0.93 mmol) was added. The reaction was left stirring at rt overnight,
then quenched at 0 °C with sat. NH<sub>4</sub>Cl, then extracted
with EtOAc. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product
was purified by silica gel column chromatography using 0–30%
EtOAc in hexanes to afford <strong>23</strong> as a colorless viscous
liquid (0.16 g, 58%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) (3:1 mixture
of rotamers) δ 4.36 (dd, <em>J</em> = 8.8, 4.3 Hz, 0.3H),
4.18 (dt, <em>J</em> = 7.9, 3.8 Hz, 1H), 3.55–3.35
(m, 2H), 2.27–2.09 (m, 1H), 2.05–1.76 (m, 4H), 1.44
(s, 3H), 1.39 (s, 7H), 0.20 (s, 7H), 0.20 (s, 3H). MS (ESI + ve):
calculated [M + Na]<sup>+</sup> C<sub>15</sub>H<sub>25</sub>NO<sub>3</sub>SiNa: 318.15; found 318.15.</p></section><section id="sec4.1.6.9"><h5 class="pmc_sec_title">
<em>tert</em>-Butyl
(<em>E</em>)-2-(3-(Diethylamino)­acryloyl)­pyrrolidine-1-carboxylate
(<strong>24</strong>)</h5>
<p>Aqueous 40% solution of diethylamine (0.10
mL, 0.99 mmol) was cooled to 0 °C, and compound <strong>23</strong> (0.15 g, 0.49 mmol) was dissolved in ethanol (2 mL). The reaction
mixture was stirred at rt for 4 h, after which it was extracted with
diethyl ether. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. Crude
product <strong>24</strong> as a colorless viscous liquid was carried
forward to next step without further purification (60 mg). <sup>1</sup>H NMR (CDCl<sub>3</sub>) (2:1 mixture of rotamers) δ 7.62 (d, <em>J</em> = 12.7 Hz, 1.5H), 5.14 (d, <em>J</em> = 12.6 Hz,
0.5H), 5.10 (d, <em>J</em> = 12.7 Hz, 1H), 4.31 (dd, <em>J</em> = 8.7, 3.4 Hz, 0.5H), 4.14 (dd, <em>J</em> = 8.5,
4.4 Hz, 1H), 3.57- 3.34 (m, 3H), 3.33–3.10 (m, 6H), 1.97–1.76
(m, 4.5H), 1.45 (s, 4.5H), 1.38 (s, 9H), 1.23–1.05 (bs, 9H).
MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>16</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub>: 297.22; found 297.22.</p></section><section id="sec4.1.6.10"><h5 class="pmc_sec_title">
<em>tert</em>-Butyl 2-(1-Ethyl-1H-pyrazol-5-yl)­pyrrolidine-1-carboxylate
and <em>tert</em>-Butyl 2-(1-Ethyl-1H-pyrazol-3-yl)­pyrrolidine-1-carboxylate
(<strong>16</strong> and <strong>25</strong>)</h5>
<p>Crude compound <strong>24</strong> (51 mg) and <strong>15</strong> (0.15 g, 0.99 mmol; based on
mmol of 23 used in previous reaction) were suspended in ethanol (2
mL) and refluxed overnight. The reaction mixture was concentrated
in vacuo, diluted with DCM, and washed with water. The organic layer
was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated
in vacuo. Crude products 16 and 25 (isomeric mixture) were carried
forward to next step without further purification (45 mg). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.37 (d, <em>J</em> = 1.8
Hz, 0.8H), 7.25 (d, <em>J</em> = 2.3 Hz, 0.1H), 5.95 (d, <em>J</em> = 1.9 Hz, 1H), 5.08–4.80 (m, 1H), 4.23–4.03
(m, 2H), 3.70–3.38 (m, 2H), 2.34–2.11 (m, 1H), 1.91
(m, 3H), 1.43 (s, 6H), 1.27 (s, 6H). MS (ESI + ve): calculated [M
+ H]<sup>+</sup> C<sub>14</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub>: 266.19; found 266.19.</p></section><section id="sec4.1.6.11"><h5 class="pmc_sec_title">2-(1-Ethyl-1H-pyrazol-5-yl)­pyrrolidine
(<strong>17</strong>) and
2-(1-Ethyl-1H-pyrazol-3-yl)­pyrrolidine (<strong>26</strong>)</h5>
<p>The crude mixture of compounds <strong>16</strong> and <strong>25</strong> (45 mg) was dissolved in 1:1 TFA/DCM at 0 °C and left stirring
at rt for 2 h. The reaction mixture was concentrated in vacuo. The
crude product was purified by silica gel column chromatography using
0–5% MeOH in DCM to afford a mixture of isomers <strong>17</strong> and <strong>26</strong> as a yellow viscous liquid (23 mg, 28% over
three steps).</p></section><section id="sec4.1.6.12"><h5 class="pmc_sec_title">1-Ethyl-5-(1-((2,4,5-trimethylphenyl)­sulfonyl)­pyrrolidin-2-yl)-1H-pyrazole
(<strong>19</strong>) and 1-Ethyl-3-(1-((2,4,5-trimethylphenyl)­sulfonyl)­pyrrolidin-2-yl)-1H-pyrazole
(<strong>27</strong>)</h5>
<p>The mixture of compounds <strong>17</strong> and <strong>26</strong> (23 mg, 0.14 mmol) was dissolved in anhyd. DCM
(1.5 mL) cooled to 0 °C. Et<sub>3</sub>N (0.08 mL, 0.56 mmol)
was added, followed by 2,4,5-trimethylbenzenesulfonyl chloride 18
(30 mg, 0.14 mmol). The reaction mixture was then left stirring at
rt overnight and concentrated in vacuo. The crude was purified by
the LC-PDA-MS instruments described earlier, with ACN/water (containing
0.1% formic acid) as the solvent system. Desired fractions were lyophilized
to afford the separated regioisomers 19 as a white solid (6 mg, 13%)
and 27 as a colorless liquid (2 mg, 4%). 19: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.49 (s, 1H), 7.22 (d, <em>J</em> = 1.9
Hz, 1H), 6.95 (s, 1H), 5.90 (d, <em>J</em> = 1.9 Hz, 1H),
5.06 (dd, <em>J</em> = 8.0, 4.2 Hz, 1H), 4.11 (ddt, <em>J</em> = 25.7, 14.1, 7.1 Hz, 2H), 3.64 (dt, <em>J</em> = 10.0, 7.3 Hz, 1H), 3.42 (ddd, <em>J</em> = 10.0, 7.2,
5.3 Hz, 1H), 2.42 (s, 3H), 2.31 (dq, <em>J</em> = 12.3, 7.9
Hz, 1H), 2.20 (d, <em>J</em> = 12.0 Hz, 6H), 2.12–1.95
(m, 2H), 1.88 (ddt, <em>J</em> = 12.0, 6.8, 4.7 Hz, 1H), 1.38
(t, <em>J</em> = 7.2 Hz, 3H).<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 142.7, 142.3, 138.2, 135.2, 134.4, 134.3, 133.8,
130.6, 104.1, 54.3, 48.3, 44.2, 34.6, 24.6, 19.8, 19.7, 19.2, 15.8.
MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>S: 348.17; found 348.17. 27: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7 7.63 (s, 1H), 7.15 (d, <em>J</em> = 2.2 Hz, 1H), 6.95 (s, 1H), 6.07 (d, <em>J</em> = 2.2 Hz, 1H), 4.99 (dd, <em>J</em> = 7.3, 4.2 Hz, 1H),
4.03 (q, <em>J</em> = 7.3 Hz, 2H), 3.55–3.42 (m, 2H),
2.48 (s, 3H), 2.22 (d, <em>J</em> = 2.8 Hz, 6H), 2.20–2.08
(m, 2H), 2.03 (ddt, <em>J</em> = 16.5, 9.2, 6.0 Hz, 1H), 1.90
(dtt, <em>J</em> = 12.0, 6.9, 4.8 Hz, 1H), 1.38 (t, <em>J</em> = 7.3 Hz, 3H).<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ
153.6, 141.6, 135.3, 134.2, 133.7, 131.1, 128.5, 104.0, 57.6, 48.4,
46.9, 34.1, 24.8, 20.2, 19.7, 19.3, 15.7. MS (ESI + ve): calculated
[M + H]<sup>+</sup> C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>S: 348.17; found 348.18.</p></section><section id="sec4.1.6.13"><h5 class="pmc_sec_title">Ethyl 1-Phenyl-3-(thiophen-2-yl)-1H-pyrazole-5-carboxylate
(<strong>30</strong>)</h5>
<p>Compounds <strong>28</strong> (0.22 mL, 2.21
mmol)
and <strong>29</strong> (0.50 g, 2.21 mmol) were dissolved in anhyd. EtOH
(10 mL) and heated at 70 °C for overnight. The reaction mixture
was concentrated in vacuo, then purified by Biotage using 0–30%
EtOAc in hexanes to afford <strong>30</strong> as a yellow solid (0.45
g, 68%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.45–7.37
(m, 5H), 7.28 (dd, <em>J</em> = 5.1, 1.2 Hz, 1H), 7.08 (s,
1H), 6.93 (dd, <em>J</em> = 5.1, 3.7 Hz, 1H), 6.82 (dd, <em>J</em> = 3.7, 1.2 Hz, 1H), 4.44 (q, <em>J</em> = 7.1
Hz, 2H), 1.41 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C
NMR (CDCl<sub>3</sub>) δ 162.3, 144.3, 139.2, 138.8, 130.2,
129.3, 129.2, 127.2, 127.8, 127.2, 126.7, 109.6, 61.3, 14.5. MS (ESI
+ ve): calculated [M + H]<sup>+</sup> C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub>S: 299.09; found 299.09.</p></section><section id="sec4.1.6.14"><h5 class="pmc_sec_title">1-Phenyl-3-(thiophen-2-yl)-1H-pyrazole-5-carboxylic
acid (<strong>31</strong>)</h5>
<p>Compound <strong>30 (</strong>0.45 g,
1.50 mmol)
was dissolved in EtOH (5 mL), and 10% aq KOH (2 mL) was added. The
reaction mixture was refluxed for 3 h, then cooled to rt. Following
acidification with 1 N HCl, the mixture was concentrated in vacuo
to afford <strong>31</strong>which was carried forward to the next reaction
without further purification (0.51 g). <sup>1</sup>H NMR (MeOD-<em>d</em>
<sub>4</sub>) δ 7.56–7.38 (m, 6H), 7.09 (s,
1H), 7.01–6.92 (m, 2H). MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>14</sub>H<sub>11</sub>N<sub>2</sub>O<sub>2</sub>S:
271.05; found 271.05.</p></section><section id="sec4.1.6.15"><h5 class="pmc_sec_title">Methyl 2-(1-(1-Phenyl-3-(thiophen-2-yl)-1H-pyrazole-5-carbonyl)­piperidin-4-yl)­acetate
(<strong>33</strong>)</h5>
<p>Crude <strong>31</strong> (0.51 g), EDC·HCl
(0.52 g, 2.70 mmol; based on mmol of <strong>30</strong> used in previous
reaction), and HOBt·H<sub>2</sub>O (0.46 g, 2.70 mmol) were suspended
in anhyd. DCM (10 mL) at 0 °C. DIPEA (0.42 mL, 2.40 mmol) was
added and the stirring continued at 0 °C for 0.5 h. Compound <strong>32</strong> (0.46 g, 2.40 mmol) was added, and the reaction was stirred
at 0 °C for 0.5 h, then overnight at rt. The reaction mixture
was diluted with DCM and washed with water. The organic layer was
dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated
in vacuo. The crude product was purified by Biotage using 0–50%
EtOAc in hexanes to afford <strong>33</strong> as an off-white solid (0.52
g, 85% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ
7.44–7.34 (m, 5H), 7.30–7.27 (m, 1H), 6.94 (dd, <em>J</em> = 5.1, 3.6 Hz, 1H), 6.91 (s, 1H), 6.84 (dd, <em>J</em> = 3.6, 1.2 Hz, 1H), 4.77 (t, <em>J</em> = 17.2 Hz, 2H),
3.67 (d, <em>J</em> = 1.5 Hz, 3H), 3.17 (t, <em>J</em> = 13.3 Hz, 1H), 2.86–2.75 (m, 1H), 2.28 (dd, <em>J</em> = 7.1, 2.5 Hz, 2H), 2.15–2.05 (m, 1H), 1.81 (dd, <em>J</em> = 24.8, 13.2 Hz, 2H), 1.31 (dd, <em>J</em> = 11.7,
5.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 172.9,
162.7, 147.7, 139.5, 137.8, 130.6, 129.2, 128.8, 127.8, 127.5, 127.1,
126.3, 109.8, 51.7, 47.3, 42.8, 40.8, 33.4, 32.8, 31.8. HRMS (ESI
+ ve): calculated [M + H]<sup>+</sup> C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub>S: 410.1533; found 410.1528.
</p></section><section id="sec4.1.6.16"><h5 class="pmc_sec_title">Methyl 2-(1-(1-Phenyl-3-(thiophen-2-yl)-1H-pyrazole-5-carbonyl)­piperidin-4-yl)­acetate
(<strong>34</strong>)</h5>
<p>Compound <strong>33</strong> (0.050 g, 0.122
mmol) was dissolved in EtOH (1 mL), and 10% aq KOH (0.5 mL) was added.
The reaction mixture was stirred at rt for 6 h. Following acidification
with 1 N HCl, the mixture was concentrated in vacuo and purified by
silica gel pad using 10% MeOH in DCM to afford <strong>34</strong> as
an off-white solid (0.04 g, 88%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45–7.34
(m, 5H), 7.29 (dd, <em>J</em> = 5.2, 1.1 Hz, 1H), 6.95 (dd, <em>J</em> = 5.2, 3.7 Hz, 1H), 6.93 (s, 1H), 6.84 (dd, <em>J</em> = 3.6, 1.2 Hz, 1H), 4.79 (dd, <em>J</em> = 25.9, 13.4 Hz,
2H), 3.18 (t, <em>J</em> = 12.8 Hz, 1H), 2.81 (t, <em>J</em> = 12.7 Hz, 1H), 2.32 (dd, <em>J</em> = 7.1, 2.4
Hz, 2H), 2.11 (dd, <em>J</em> = 11.4, 7.8, 3.7 Hz, 1H), 1.86
(dd, <em>J</em> = 24.5, 13.3 Hz, 2H), 1.42–1.28 (m,
2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.4, 162.8, 147.5,
139.4, 137.9, 130.5, 129.2, 128.9, 127.8, 127.5, 127.2, 126.3, 109.9,
47.4, 42.4, 40.9, 33.1, 32.7, 31.8. MS (ESI + ve): calculated [M +
H]<sup>+</sup> C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>S: 396.14; found 396.14.</p></section><section id="sec4.1.6.17"><h5 class="pmc_sec_title">Ethyl 5-Amino-1-phenyl-1H-pyrazole-4-carboxylate
(<strong>36</strong>)</h5>
<p>Compounds <strong>28</strong> (0.12 mL, 1.77
mmol<strong>)</strong> and <strong>35</strong> (0.30 g, 1.77 mmol) were dissolved
in anhyd.
toluene (3 mL) in a microwave vial. The reaction mixture was subjected
to microwave irradiation at 120 °C for 1 h. The reaction mixture
was concentrated in vacuo to afford <strong>36</strong>, which was carried
forward to the next reaction without further purification (0.35 g). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.00 (s, 0H), 7.78 (s, 1H),
7.56–7.48 (m, 4H), 7.40 (ddt, <em>J</em> = 7.3, 6.1,
1.9 Hz, 1H), 4.30 (q, <em>J</em> = 7.1 Hz, 2H), 1.36 (t, <em>J</em> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ
172.3, 164.7, 149.2, 140.8, 137.7, 129.9, 128.3, 123.9, 96.3, 59.8,
14.7.</p></section><section id="sec4.1.6.18"><h5 class="pmc_sec_title">Ethyl 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylate
(<strong>38</strong>)</h5>
<p>Crude <strong>36</strong> (0.35 g) was dissolved
in acetic acid (3 mL), and <strong>37</strong> (0.19 mL, 1.77 mmol; based
on mmol of <strong>28</strong> used in previous reaction) was added dropwise.
The reaction mixture was refluxed for 3 h then concentrated in vacuo.
The crude product was purified by silica gel column chromatography
using 0–20% EtOAc in hexanes to afford <strong>38</strong> as a
yellow solid (0.28 g, 57% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.15 (s, 1H), 7.37–7.31 (m, 3H), 7.14–7.09
(m, 2H), 6.70–6.67 (m, 2H), 6.30–6.27 (m, 2H), 4.24
(q, <em>J</em> = 7.1 Hz, 2H), 1.26 (t, <em>J</em> =
7.1 Hz, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.8,
142.1, 140.2, 137.9, 129.4, 128.5, 123.0, 122.7, 110.9, 109.8, 60.6,
14.3. MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>16</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>: 282.12; found 282.12.</p></section><section id="sec4.1.6.19"><h5 class="pmc_sec_title">1-Phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylic acid (<strong>39</strong>)</h5>
<p>Compound <strong>38</strong> (0.11 g, 0.37 mmol)
was dissolved in ethanol (2 mL), and 10% aq KOH (1 mL) was added.
The reaction mixture was refluxed for 2 h then cooled to rt. Following
acidification with 1 N HCl, the mixture was concentrated in vacuo
to afford <strong>39</strong>, which was carried forward to the next reaction
without further purification (0.19 g). <sup>1</sup>H NMR (MeOD-<em>d</em>
<sub>4</sub>) δ 8.15 (s, 1H), 7.38–7.33 (m,
3H), 7.18–7.11 (m, 2H), 6.74–6.72 (m, 2H), 6.22–6.20
(m, 2H). <sup>13</sup>C NMR (MeOD-<em>d</em>
<sub>4</sub>)
δ 143.3, 130.3, 129.7, 124.7, 123.9, 111.5. MS (ESI + ve): calculated
[M + H]<sup>+</sup> C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>: 254.09; found 254.09.</p></section><section id="sec4.1.6.20"><h5 class="pmc_sec_title">1-Phenyl-5-(1H-pyrrol-1-yl)-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide
(<strong>41</strong>)</h5>
<p>Crude <strong>39</strong> (0.14 g), EDC·HCl
(86 mg, 0.45 mmol; based on mmol of <strong>38</strong> used in previous
reaction), and HOBt·H<sub>2</sub>O (76 mg, 0.45 mmol) were suspended
in anhyd. DCM (3 mL) at 0 °C. DIPEA (0.07 mL, 0.37 mmol) was
added and the stirring continued at 0 °C for 0.5 h. Compound <strong>40</strong> (37 mg, 0.37 mmol) was added, and the reaction was stirred
at 0 °C for 0.5 h, then overnight at rt. The reaction mixture
was diluted with DCM and washed with water. The organic layer was
dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated
in vacuo. The crude product was purified by Biotage using 0–50%
EtOAc in hexanes to afford <strong>41</strong> as a white solid (22 mg,
18% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ
8.34 (s, 1H), 7.41 (d, <em>J</em> = 3.6 Hz, 1H), 7.36 (dd, <em>J</em> = 5.1, 2.0 Hz, 3H), 7.21–7.14 (m, 2H), 6.96 (d, <em>J</em> = 3.5 Hz, 1H), 6.84 (t, <em>J</em> = 2.1 Hz, 2H),
6.55 (t, <em>J</em> = 2.1 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 158.0, 157.5, 141.8, 137.9, 137.4, 129.6, 128.8,
122.6, 114.1, 113.5, 112.2. MS (ESI + ve): calculated [M + H]<sup>+</sup> C<sub>17</sub>H<sub>14</sub>N<sub>5</sub>OS: 336.09; found
336.09.</p></section></section></section><section id="sec4.2"><h3 class="pmc_sec_title">Biology</h3>
<section id="sec4.2.1"><h4 class="pmc_sec_title">Phagocytosis Assay</h4>
<p>The MMA to screen compounds for
their ability to inhibit phagocytosis was performed as previously
described.<em>
,
</em> Briefly, PBMCs were layered onto
chamber slides, and monocytes were purified by adherence after 1 h
at 37 °C with 5% CO<sub>2</sub>. Compounds were solubilized in
100% DMSO and then diluted in RPMI to the final concentration of 5
μM, as previously reported. Corresponding
DMSO volumes in RPMI were used as a control. Final DMSO concentration
used was ≤1% vol/vol. After 1 h, indicator Rh-positive red
cells opsonized with anti-RhD were added to the chamber slides and
then further incubated for 2 h before fixing and counting phagocytosed
RBCs using phase-contrast microscopy. As a positive control for inhibition, IVIG, known to inhibit phagocytosis
due to blocking of FcγRs, was used. The phagocytosis index (PI) was determined as the number of phagocytosed
RBCs in 300 monocytes.</p>
<table class="disp-formula p" id="eq1"><tr>
<td class="formula"><math id="d1e3167" display="block"><mi>PI</mi><mo>=</mo><mfrac><mrow><mi>#</mi><mspace width="0.25em"></mspace><mi>of</mi><mspace width="0.25em"></mspace><mi>phagocytic</mi><mspace width="0.25em"></mspace><mi>RBCs</mi></mrow><mrow><mn>300</mn><mspace width="0.25em"></mspace><mi>monocytes</mi></mrow></mfrac><mo>×</mo><mn>100</mn></math></td>
<td class="label">1</td>
</tr></table></section><section id="sec4.2.2"><h4 class="pmc_sec_title">Dose-Inhibitory Response and IC<sub>50</sub>
</h4>
<p>MMAs (as
explained in the previous section) were repeated with different concentration
of the compounds <strong>5</strong>, <strong>9a</strong>–<strong>e</strong>, <strong>19</strong>, <strong>27</strong>, <strong>33</strong>, <strong>34</strong>, and <strong>41</strong> including 100, 50, 25, 10, 5, 2.5, 1, and 0.5
μM with human PBMCs. The percent inhibition of phagocytosis
was determined by comparing the PI in each treated sample to the PI
in the untreated sample, which was determined by normalizing the PI
concentration in each treated sample (phagocytosis of opsonized RBCs
with vehicle only, representing 100% phagocytosis).</p>
<table class="disp-formula p" id="eq2"><tr>
<td class="formula"><math id="d1e3212" display="block"><mo>%</mo><mspace width="0.25em"></mspace><mi>Inhibition</mi><mo>=</mo><mn>1</mn><mo>−</mo><mfrac><mrow><mi>PI</mi><mspace width="0.25em"></mspace><mo stretchy="false">(</mo><mi>treated</mi><mo stretchy="false">)</mo></mrow><mrow><mi>PI</mi><mspace width="0.25em"></mspace><mo stretchy="false">(</mo><mi>untreated</mi><mo stretchy="false">)</mo></mrow></mfrac><mo>×</mo><mn>100</mn></math></td>
<td class="label">2</td>
</tr></table>
<p>To
determine the IC<sub>50</sub> values, normalized inhibition data were
used to perform
nonlinear fit to dose–response inhibition equations with variable
slopes using GraphPad Prism 7.</p>
<table class="disp-formula p" id="eq3"><tr>
<td class="formula"><math id="d1e3246" display="block"><mi>Y</mi><mo>=</mo><mfrac><mn>100</mn><mrow><mn>1</mn><mo>+</mo><msup><mrow><mo stretchy="true">(</mo><mfrac><mi>x</mi><mrow><msub><mi>IC</mi><mn>50</mn></msub></mrow></mfrac><mo stretchy="true">)</mo></mrow><mi>HillSlope</mi></msup></mrow></mfrac></math></td>
<td class="label">3</td>
</tr></table></section><section id="sec4.2.3"><h4 class="pmc_sec_title">Pharmacokinetics of <strong>33</strong>
</h4>
<p>All protocols involving
animals were approved by the Institutional Animal Care Committee at
University Health Network (UHN), Toronto, Canada (Animal Use Protocol
# 7014). Seven weeks old male and female mice BALB/cJ (Stock# JAX:651)
were purchased from Jackson Laboratories (Bar Harbor, Maine, USA).
Animals were housed in the Animal Resource Center facility at UHN
and maintained under regulated light and temperature conditions. The
food and water were available ad libitum in each cage. Mice were housed
for 1 week in groups of five per cage to acclimate to the facilities.</p>
<p>Pharmacokinetic analysis of <strong>33</strong> was conducted in healthy
male and female mice (<em>n</em> = 27 per sex, 18–22
g in weight). Ten mM stock of the test compound was prepared in DMSO.
Mice received 0.1 mL IP injection of 1 mg/kg <strong>33</strong> dissolved
in 10% DMSO and PBS. The pH of the sample was adjusted to 6 with 0.1
N HCl to facilitate solubilization of <strong>33</strong>. Blood was collected
via cardiac puncture from animals anesthetized with inhaled isoflurane
(induction: 5%, maintenance: 2.5%) at the following time points: 0
(predose), 5, 15, 30 min, 1, 2, 4, 6, and 24 h. Blood from three mice
was collected at each time point. Samples were collected in <em>k</em>
<sub>2</sub>EDTA tubes (Sarstedt) to obtain plasma. Samples
were spiked with internal standard, cannabidiol (CBD), at 25 μg/mL
final concentration and centrifuged at room temperature for 3 min
at 10,000 rpm to obtain plasma. The plasma was collected, stored in
microcentrifuge tubes, and frozen at −80 °C. Frozen plasma
samples (PK and standard curves) were lyophilized for 18 h at −55
°C and 0.700 mbar vacuum. Lyophilized powder was resuspended
in MeOH containing 0.1% formic acid and centrifuged (5 min at 12,000
rpm) at room temperature to obtain clear supernatant that was mixed
with equal volume of H<sub>2</sub>O (0.1% formic acid) and centrifuged
again to remove any insoluble material (10 min at 12,000 rpm). The
samples were injected into LC–MS to be analyzed for the presence
of <strong>33</strong>, <strong>34</strong> and other possible metabolites.</p>
<p>Samples were analyzed using Waters Acquity UPLC system equipped
with Quaternary Solvent Manager, Waters MS 3100 mass spectrometer,
Sample Manager FTN, Acquity UPLC BEH column (2.1 mm × 50 mm,
C-18, 1.7 μm ID). The mobile phase for UPLC-MS analysis consisted
of H<sub>2</sub>O (A) and MeOH (B), each with 0.1% formic acid. The
gradient was programmed as follows: 0–4.5 min (50% A/50% B
to 0% A/100% B), 4.5–5.0 min (0% A/100% B); 5.0–5.2
min (0% A/100% B to 50% A/50% B) and 5.2–6 min (50% A/50% B).
The flow rate was 0.6 mL/min, and all samples were analyzed in triplicate.
The mass scan (150–650 <em>m</em>/<em>z</em>), individual masses of <strong>34</strong> (410.5 <em>m</em>/<em>z</em>), <strong>34</strong> (396.5 <em>m</em>/<em>z</em>) and the internal standard (315.5 <em>m</em>/<em>z</em>) were recorded in positive and negative modes. The chromatograms
were integrated using Empower 3 software. To generate standard curves,
the AUC ratios (analyte/CBD) were plotted vs analyte concentration
used to spike blood samples. The concentrations of the analyte were
derived from the standard curve.</p></section></section></section><section id="sec57"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="sifile1"><div class="media p"><div class="caption">
<a href="/articles/instance/12332598/bin/ao5c03645_si_001.pdf" data-ga-action="click_feat_suppl" class="usa-link">ao5c03645_si_001.pdf</a><sup> (2.2MB, pdf) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>M.L. was a recipient of a CBS Graduate Fellowship
Program (GFP) award. The authors thank the Pathology Core at The Centre
for Phenogenomics (TCP) for their biochemistry analysis, histopathology
report and their insightful discussions.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Glossary</h2>
<h3>Abbreviations</h3>
<dl class="def-list" id="dl1">
<dt>ACN</dt>
<dd><p>acetonitrile</p></dd>
<dt>DIPEA</dt>
<dd><p>
<em>N</em>,<em>N</em>-diisopropylethylamine</p></dd>
<dt>EDC·HCl</dt>
<dd><p>1-ethyl-3-(3-(dimethylamino)­propyl)­carbodiimide hydrochloride</p></dd>
<dt>HATU</dt>
<dd><p>hexafluorophosphate
azabenzotriazole tetramethyl uronium</p></dd>
<dt>HOBt·H<sub>2</sub>O</dt>
<dd><p>1-hydroxybenzotriazole
hydrate</p></dd>
<dt>LDH</dt>
<dd><p>lactate
dehydrogenase</p></dd>
<dt>MMA</dt>
<dd><p>monocyte monolayer assay</p></dd>
<dt>MTT</dt>
<dd><p>3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide</p></dd>
<dt>PBMC</dt>
<dd><p>peripheral blood
mononuclear cell</p></dd>
<dt>SHP-1</dt>
<dd><p>Src homology-2 domain–containing phosphatase-1</p></dd>
<dt>SHIP-1</dt>
<dd><p>SH-2 containing inositol
5′ polyphosphatase 1</p></dd>
<dt>UPLC</dt>
<dd><p>ultraperformance liquid chromatography.</p></dd>
</dl></section><section id="notes2"><p>The Supporting Information is
available free of charge at <a href="https://pubs.acs.org/doi/10.1021/acsomega.5c03645?goto=supporting-info" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pubs.acs.org/doi/10.1021/acsomega.5c03645</a>.</p>
<ul id="silist" class="list" style="list-style-type:none"><li><p>NMR for intermediate and
final compounds along with
purity data for final compounds (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.5c03645/suppl_file/ao5c03645_si_001.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">PDF</a>)</p></li></ul></section><section id="notes1"><h2>∇.</h2>
<p>Humber
River Health, North York, Ontario, Canada M3M 0B2</p></section><section id="notes3"><p>The manuscript
was written through contributions of all authors.</p></section><section id="notes4"><p>This research
was funded by the Canadian Blood Services (CBS) Intramural Funding
Program, grant number XT00136.</p></section><section id="notes5"><p>The authors
declare no competing financial interest.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ol class="ref-list font-sm">
<li id="ref1">
<cite>Lambert M. P., Gernsheimer T. B.. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129:2829–2835. doi: 10.1182/blood-2017-03-754119.</cite> [<a href="https://doi.org/10.1182/blood-2017-03-754119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5813736/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28416506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Clinical%20updates%20in%20adult%20immune%20thrombocytopenia&amp;author=M.%20P.%20Lambert&amp;author=T.%20B.%20Gernsheimer&amp;volume=129&amp;publication_year=2017&amp;pages=2829-2835&amp;pmid=28416506&amp;doi=10.1182/blood-2017-03-754119&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref2">
<cite>Neunert C., Terrell D. R., Arnold D. M., Buchanan G., Cines D. B., Cooper N., Cuker A., Despotovic J. M., George J. N., Grace R. F., Kühne T., Kuter D. J., Lim W., McCrae K. R., Pruitt B., Shimanek H., Vesely S. K.. American Society of Hematology 2019
guidelines for immune thrombocytopenia. Blood
Adv. 2019;3:3829–3866. doi: 10.1182/bloodadvances.2019000966.</cite> [<a href="https://doi.org/10.1182/bloodadvances.2019000966" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6963252/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31794604/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv.&amp;title=American%20Society%20of%20Hematology%202019%20guidelines%20for%20immune%20thrombocytopenia&amp;author=C.%20Neunert&amp;author=D.%20R.%20Terrell&amp;author=D.%20M.%20Arnold&amp;author=G.%20Buchanan&amp;author=D.%20B.%20Cines&amp;volume=3&amp;publication_year=2019&amp;pages=3829-3866&amp;pmid=31794604&amp;doi=10.1182/bloodadvances.2019000966&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>Erratum
in: <em>Blood Adv.</em>
<strong>2020</strong>, <em>4</em>, 252.</cite>
</li>
<li id="ref3">
<cite>

Petz, L. D.
; 
Branch, D. R.
 In Methods in Hematology:
Immune Cytopenias, 
McMillan, R.
, Ed.; Churchill Livingstone: New York, 1983; Vol. 9, pp. 9–48.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Methods%20in%20Hematology:%20Immune%20Cytopenias&amp;publication_year=1983&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref4">
<cite>

Petz, L. D.
; 
Garratty, G.
. 
Immune Hemolytic Anemias, 2nd ed.; 
Petz, L. D.
; 
Garratty, G.
, Eds.; Churchill Livingstone: Philadelphia, USA, 2004.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Immune%20Hemolytic%20Anemias&amp;publication_year=2004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref5">
<cite>Fujita M., Kawabata H., Oka T., Hishizawa M., Kitano T., Kondo T., Yamashita K., Yurugi K., Hirai H., Maekawa T., Takaori-Kondo A.. A rare case
of adult autoimmune neutropenia successfully treated with prednisolone. Int. Med. 2017;56:1415–1419. doi: 10.2169/internalmedicine.56.7619.</cite> [<a href="https://doi.org/10.2169/internalmedicine.56.7619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5498209/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28566608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20Med.&amp;title=A%20rare%20case%20of%20adult%20autoimmune%20neutropenia%20successfully%20treated%20with%20prednisolone&amp;author=M.%20Fujita&amp;author=H.%20Kawabata&amp;author=T.%20Oka&amp;author=M.%20Hishizawa&amp;author=T.%20Kitano&amp;volume=56&amp;publication_year=2017&amp;pages=1415-1419&amp;pmid=28566608&amp;doi=10.2169/internalmedicine.56.7619&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref6">
<cite>Swinkels M., Rijkers M., Voorberg J., Vidarsson G., Leebeek F. W. G., Jansen A. J. G.. Emerging Concepts
in Immune Thrombocytopenia. Front. Immunol. 2018;9:880. doi: 10.3389/fimmu.2018.00880.</cite> [<a href="https://doi.org/10.3389/fimmu.2018.00880" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5937051/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29760702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Immunol.&amp;title=Emerging%20Concepts%20in%20Immune%20Thrombocytopenia&amp;author=M.%20Swinkels&amp;author=M.%20Rijkers&amp;author=J.%20Voorberg&amp;author=G.%20Vidarsson&amp;author=F.%20W.%20G.%20Leebeek&amp;volume=9&amp;publication_year=2018&amp;pages=880&amp;pmid=29760702&amp;doi=10.3389/fimmu.2018.00880&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref7">
<cite>de
Sauvage F. J., Carver-Moore K., Luoh S. M., Ryan A., Dowd M., Eaton D. L., Moore M. W.. Physiological regulation
of early and late stages of megakaryocytopoiesis by thrombopoietin. J. Exp. Med. 1996;183:651–656. doi: 10.1084/jem.183.2.651.</cite> [<a href="https://doi.org/10.1084/jem.183.2.651" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2192470/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8627177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Exp.%20Med.&amp;title=Physiological%20regulation%20of%20early%20and%20late%20stages%20of%20megakaryocytopoiesis%20by%20thrombopoietin&amp;author=F.%20J.%20de%20Sauvage&amp;author=K.%20Carver-Moore&amp;author=S.%20M.%20Luoh&amp;author=A.%20Ryan&amp;author=M.%20Dowd&amp;volume=183&amp;publication_year=1996&amp;pages=651-656&amp;pmid=8627177&amp;doi=10.1084/jem.183.2.651&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref8">
<cite>Grozovsky R., Begonja A. J., Liu K., Visner G., Hartwig J. H., Falet H., Hoffmeister K. M.. The Ashwell-Morell receptor regulates
hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat. Med. 2015;21:47–54. doi: 10.1038/nm.3770.</cite> [<a href="https://doi.org/10.1038/nm.3770" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4303234/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25485912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=The%20Ashwell-Morell%20receptor%20regulates%20hepatic%20thrombopoietin%20production%20via%20JAK2-STAT3%20signaling&amp;author=R.%20Grozovsky&amp;author=A.%20J.%20Begonja&amp;author=K.%20Liu&amp;author=G.%20Visner&amp;author=J.%20H.%20Hartwig&amp;volume=21&amp;publication_year=2015&amp;pages=47-54&amp;pmid=25485912&amp;doi=10.1038/nm.3770&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref9">
<cite>Grozovsky R., Giannini S., Falet H., Hoffmeister K. M.. Regulating
billions of blood platelets: glycans and beyond. Blood. 2015;126:1877–1884. doi: 10.1182/blood-2015-01-569129.</cite> [<a href="https://doi.org/10.1182/blood-2015-01-569129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4608239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26330242/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Regulating%20billions%20of%20blood%20platelets:%20glycans%20and%20beyond&amp;author=R.%20Grozovsky&amp;author=S.%20Giannini&amp;author=H.%20Falet&amp;author=K.%20M.%20Hoffmeister&amp;volume=126&amp;publication_year=2015&amp;pages=1877-1884&amp;pmid=26330242&amp;doi=10.1182/blood-2015-01-569129&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref10">
<cite>Neschadim A., Kotra L. P., Branch D. R.. Small molecule phagocytosis inhibitors
for immune cytopenias. Autoimmun. Rev. 2016;15:843–847. doi: 10.1016/j.autrev.2016.06.004.</cite> [<a href="https://doi.org/10.1016/j.autrev.2016.06.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27296447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Autoimmun.%20Rev.&amp;title=Small%20molecule%20phagocytosis%20inhibitors%20for%20immune%20cytopenias&amp;author=A.%20Neschadim&amp;author=L.%20P.%20Kotra&amp;author=D.%20R.%20Branch&amp;volume=15&amp;publication_year=2016&amp;pages=843-847&amp;pmid=27296447&amp;doi=10.1016/j.autrev.2016.06.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref11">
<cite>Loriamini M., Cserti-Gazdewich C., Branch D. R.. Autoimmune hemolytic anemias: classifications,
pathophysiology, diagnoses and management. Int.
J. Mol. Sci. 2024;25:4296. doi: 10.3390/ijms25084296.</cite> [<a href="https://doi.org/10.3390/ijms25084296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11049952/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38673882/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Autoimmune%20hemolytic%20anemias:%20classifications,%20pathophysiology,%20diagnoses%20and%20management&amp;author=M.%20Loriamini&amp;author=C.%20Cserti-Gazdewich&amp;author=D.%20R.%20Branch&amp;volume=25&amp;publication_year=2024&amp;pages=4296&amp;pmid=38673882&amp;doi=10.3390/ijms25084296&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref12">
<cite>Almizraq R. J., Branch D. R.. Efficacy and mechanism
of intravenous immunoglobulin
treatment for immune thrombocytopenia in adults. Ann. Blood. 2020;5:35.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Blood.&amp;title=Efficacy%20and%20mechanism%20of%20intravenous%20immunoglobulin%20treatment%20for%20immune%20thrombocytopenia%20in%20adults&amp;author=R.%20J.%20Almizraq&amp;author=D.%20R.%20Branch&amp;volume=5&amp;publication_year=2020&amp;pages=35&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref13">
<cite>Stasi R.. Immune thrombocytopenia:
pathophysiologic and clinical update. Semin.
Thromb. Hemost. 2012;38:454–462. doi: 10.1055/s-0032-1305780.</cite> [<a href="https://doi.org/10.1055/s-0032-1305780" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22753097/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin.%20Thromb.%20Hemost.&amp;title=Immune%20thrombocytopenia:%20pathophysiologic%20and%20clinical%20update&amp;author=R.%20Stasi&amp;volume=38&amp;publication_year=2012&amp;pages=454-462&amp;pmid=22753097&amp;doi=10.1055/s-0032-1305780&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref14">
<cite>George J. N., Woolf S. H., Raskob G. E., Wasser J. S., Aledort L. M., Ballem P. J., Blanchette V. S., Bussel J. B., Cines D. B., Kelton J. G., Lichtin A. E., McMillan R., Okerbloom J. A., Regan D. H., Warrier I.. Idiopathic thrombocytopenic purpura:
a practice guideline developed by explicit methods for the American
Society of Hematology. Blood. 1996;88:3–40.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/8704187/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Idiopathic%20thrombocytopenic%20purpura:%20a%20practice%20guideline%20developed%20by%20explicit%20methods%20for%20the%20American%20Society%20of%20Hematology&amp;author=J.%20N.%20George&amp;author=S.%20H.%20Woolf&amp;author=G.%20E.%20Raskob&amp;author=J.%20S.%20Wasser&amp;author=L.%20M.%20Aledort&amp;volume=88&amp;publication_year=1996&amp;pages=3-40&amp;pmid=8704187&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref15">
<cite>Lewis B. J. B., Ville J., Blacquiere M., Cen S., Spirig R., Zuercher A. W., Käsermann F. K., Branch D. R.. Using the K/BxN
mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation
of potential immunoglobulin-based therapeutic agents, including IVIg
and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer. BMC Immunol. 2019;20:44. doi: 10.1186/s12865-019-0328-6.</cite> [<a href="https://doi.org/10.1186/s12865-019-0328-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6894239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31801459/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Immunol.&amp;title=Using%20the%20K/BxN%20mouse%20model%20of%20endogenous,%20chronic,%20rheumatoid%20arthritis%20for%20the%20evaluation%20of%20potential%20immunoglobulin-based%20therapeutic%20agents,%20including%20IVIg%20and%20Fc-%CE%BCTP-L309C,%20a%20recombinant%20IgG1%20Fc%20hexamer&amp;author=B.%20J.%20B.%20Lewis&amp;author=J.%20Ville&amp;author=M.%20Blacquiere&amp;author=S.%20Cen&amp;author=R.%20Spirig&amp;volume=20&amp;publication_year=2019&amp;pages=44&amp;pmid=31801459&amp;doi=10.1186/s12865-019-0328-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref16">
<cite>Thompson J. C., Klima J., Despotovic J. M., O’Brien S. H.. Anti-D
immunoglobulin therapy for pediatric ITP: before and after the FDA’s
black box warning. Pediatr. Blood Cancer. 2013;60:E149–151. doi: 10.1002/pbc.24633.</cite> [<a href="https://doi.org/10.1002/pbc.24633" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23813881/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr.%20Blood%20Cancer&amp;title=Anti-D%20immunoglobulin%20therapy%20for%20pediatric%20ITP:%20before%20and%20after%20the%20FDA%E2%80%99s%20black%20box%20warning&amp;author=J.%20C.%20Thompson&amp;author=J.%20Klima&amp;author=J.%20M.%20Despotovic&amp;author=S.%20H.%20O%E2%80%99Brien&amp;volume=60&amp;publication_year=2013&amp;pages=E149-151&amp;pmid=23813881&amp;doi=10.1002/pbc.24633&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref17">
<cite>Ghanima W., Godeau B., Cines D. B., Bussel J. B.. How I treat immune
thrombocytopenia: the choice between splenectomy or a medical therapy
as a second-line treatment. Blood. 2012;120:960–969. doi: 10.1182/blood-2011-12-309153.</cite> [<a href="https://doi.org/10.1182/blood-2011-12-309153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22740443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=How%20I%20treat%20immune%20thrombocytopenia:%20the%20choice%20between%20splenectomy%20or%20a%20medical%20therapy%20as%20a%20second-line%20treatment&amp;author=W.%20Ghanima&amp;author=B.%20Godeau&amp;author=D.%20B.%20Cines&amp;author=J.%20B.%20Bussel&amp;volume=120&amp;publication_year=2012&amp;pages=960-969&amp;pmid=22740443&amp;doi=10.1182/blood-2011-12-309153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref18">
<cite>Stasi R., Del Poeta G., Stipa E., Evangelista M. L., Trawinska M. M., Cooper N., Amadori S.. Response to B-cell
depleting therapy with rituximab reverts the abnormalities of T-cell
subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924–2930. doi: 10.1182/blood-2007-02-068999.</cite> [<a href="https://doi.org/10.1182/blood-2007-02-068999" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17548576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Response%20to%20B-cell%20depleting%20therapy%20with%20rituximab%20reverts%20the%20abnormalities%20of%20T-cell%20subsets%20in%20patients%20with%20idiopathic%20thrombocytopenic%20purpura&amp;author=R.%20Stasi&amp;author=G.%20Del%20Poeta&amp;author=E.%20Stipa&amp;author=M.%20L.%20Evangelista&amp;author=M.%20M.%20Trawinska&amp;volume=110&amp;publication_year=2007&amp;pages=2924-2930&amp;pmid=17548576&amp;doi=10.1182/blood-2007-02-068999&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref19">
<cite>Cooper N., Ghanima W., Hill Q. A., Nicolson P. L., Markovtsov V., Kessler C.. Recent advances in understanding
spleen tyrosine kinase
(SYK) in human biology and disease, with a focus on fostamatinib. Platelets. 2023;34:2131751.  doi: 10.1080/09537104.2022.2131751.</cite> [<a href="https://doi.org/10.1080/09537104.2022.2131751" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36331249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Platelets&amp;title=Recent%20advances%20in%20understanding%20spleen%20tyrosine%20kinase%20(SYK)%20in%20human%20biology%20and%20disease,%20with%20a%20focus%20on%20fostamatinib&amp;author=N.%20Cooper&amp;author=W.%20Ghanima&amp;author=Q.%20A.%20Hill&amp;author=P.%20L.%20Nicolson&amp;author=V.%20Markovtsov&amp;volume=34&amp;publication_year=2023&amp;pages=2131751&amp;pmid=36331249&amp;doi=10.1080/09537104.2022.2131751&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref20">
<cite>Gilreath J., Lo M., Bubalo J.. Thrombopoietin
Receptor Agonists (TPO-RAs): Drug Class
Considerations for Pharmacists. Drugs. 2021;81:1285–1305. doi: 10.1007/s40265-021-01553-7.</cite> [<a href="https://doi.org/10.1007/s40265-021-01553-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8318934/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34160821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Thrombopoietin%20Receptor%20Agonists%20(TPO-RAs):%20Drug%20Class%20Considerations%20for%20Pharmacists&amp;author=J.%20Gilreath&amp;author=M.%20Lo&amp;author=J.%20Bubalo&amp;volume=81&amp;publication_year=2021&amp;pages=1285-1305&amp;pmid=34160821&amp;doi=10.1007/s40265-021-01553-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref21">
<cite>Connell N. T., Berliner N.. Fostamatinib for the
treatment of chronic immune thrombocytopenia. Blood. 2019;133:2027–2030. doi: 10.1182/blood-2018-11-852491.</cite> [<a href="https://doi.org/10.1182/blood-2018-11-852491" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30803989/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Fostamatinib%20for%20the%20treatment%20of%20chronic%20immune%20thrombocytopenia&amp;author=N.%20T.%20Connell&amp;author=N.%20Berliner&amp;volume=133&amp;publication_year=2019&amp;pages=2027-2030&amp;pmid=30803989&amp;doi=10.1182/blood-2018-11-852491&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref22">
<cite>Cheloff A. Z., Al-Samkari H.. Avatrombopag for the treatment of immune thrombocytopenia
and thrombocytopenia of chronic liver disease. J. Blood Med. 2019;10:313–321. doi: 10.2147/JBM.S191790.</cite> [<a href="https://doi.org/10.2147/JBM.S191790" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6733339/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31565009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Blood%20Med.&amp;title=Avatrombopag%20for%20the%20treatment%20of%20immune%20thrombocytopenia%20and%20thrombocytopenia%20of%20chronic%20liver%20disease&amp;author=A.%20Z.%20Cheloff&amp;author=H.%20Al-Samkari&amp;volume=10&amp;publication_year=2019&amp;pages=313-321&amp;pmid=31565009&amp;doi=10.2147/JBM.S191790&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref23">
<cite>Gomez-Almaguer D.. Eltrombopag-based
combination treatment for immune thrombocytopenia. Ther. Adv. Hematol. 2018;9:309–317. doi: 10.1177/2040620718798798.</cite> [<a href="https://doi.org/10.1177/2040620718798798" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6187430/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30344993/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther.%20Adv.%20Hematol.&amp;title=Eltrombopag-based%20combination%20treatment%20for%20immune%20thrombocytopenia&amp;author=D.%20Gomez-Almaguer&amp;volume=9&amp;publication_year=2018&amp;pages=309-317&amp;pmid=30344993&amp;doi=10.1177/2040620718798798&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref24">
<cite>Loriamini M., Lewis-Bakker M. M., Frias Boligan K., Wang S., Holton M. B., Kotra L. P., Branch D. R.. Small Molecule
Drugs That Inhibit
Phagocytosis. Molecules. 2023;28:757. doi: 10.3390/molecules28020757.</cite> [<a href="https://doi.org/10.3390/molecules28020757" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9867408/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36677815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=Small%20Molecule%20Drugs%20That%20Inhibit%20Phagocytosis&amp;author=M.%20Loriamini&amp;author=M.%20M.%20Lewis-Bakker&amp;author=K.%20Frias%20Boligan&amp;author=S.%20Wang&amp;author=M.%20B.%20Holton&amp;volume=28&amp;publication_year=2023&amp;pages=757&amp;pmid=36677815&amp;doi=10.3390/molecules28020757&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref25">
<cite>Loriamini M., Lewis-Bakker M. M., Binnington B., Kotra L. P., Branch D. R.. Mechanism
of Small Molecule Inhibitors of Phagocytosis. J. Hematol. Clin. Res. 2023;7:011–014. doi: 10.29328/journal.jhcr.1001022.</cite> [<a href="https://doi.org/10.29328/journal.jhcr.1001022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Hematol.%20Clin.%20Res.&amp;title=Mechanism%20of%20Small%20Molecule%20Inhibitors%20of%20Phagocytosis&amp;author=M.%20Loriamini&amp;author=M.%20M.%20Lewis-Bakker&amp;author=B.%20Binnington&amp;author=L.%20P.%20Kotra&amp;author=D.%20R.%20Branch&amp;volume=7&amp;publication_year=2023&amp;pages=011-014&amp;doi=10.29328/journal.jhcr.1001022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref26">
<cite>Akula R., Xionga Y., Ibrahim H.. Electrophilic
α-cyanation of
1,3-dicarbonyl compounds. RSC Adv. 2013;3:10731–10735. doi: 10.1039/C3RA41376D.</cite> [<a href="https://doi.org/10.1039/C3RA41376D" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Adv.&amp;title=Electrophilic%20%CE%B1-cyanation%20of%201,3-dicarbonyl%20compounds&amp;author=R.%20Akula&amp;author=Y.%20Xionga&amp;author=H.%20Ibrahim&amp;volume=3&amp;publication_year=2013&amp;pages=10731-10735&amp;doi=10.1039/C3RA41376D&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref27">
<cite>Al-Mousawi S. M., Moustafa M. S., Elnagdi M. E.. Studies with 2-arylhydrazononitriles:
further investigations on the utility of 2-arylhydrazononitriles as
precursors to 1,2,3-triazole amines. J. Chem.
Res. 2007;9:515–518. doi: 10.3184/030823407X244869.</cite> [<a href="https://doi.org/10.3184/030823407X244869" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Chem.%20Res.&amp;title=Studies%20with%202-arylhydrazononitriles:%20further%20investigations%20on%20the%20utility%20of%202-arylhydrazononitriles%20as%20precursors%20to%201,2,3-triazole%20amines&amp;author=S.%20M.%20Al-Mousawi&amp;author=M.%20S.%20Moustafa&amp;author=M.%20E.%20Elnagdi&amp;volume=9&amp;publication_year=2007&amp;pages=515-518&amp;doi=10.3184/030823407X244869&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref28">
<cite>Barak D. S., Dighe S. U., Avasthi I., Batra S.. Iodine-Catalyzed Diazenylation
with Arylhydrazine Hydrochlorides in Air. J.
Org. Chem. 2018;83:3537–3546. doi: 10.1021/acs.joc.7b03149.</cite> [<a href="https://doi.org/10.1021/acs.joc.7b03149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29486127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Org.%20Chem.&amp;title=Iodine-Catalyzed%20Diazenylation%20with%20Arylhydrazine%20Hydrochlorides%20in%20Air&amp;author=D.%20S.%20Barak&amp;author=S.%20U.%20Dighe&amp;author=I.%20Avasthi&amp;author=S.%20Batra&amp;volume=83&amp;publication_year=2018&amp;pages=3537-3546&amp;pmid=29486127&amp;doi=10.1021/acs.joc.7b03149&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref29">
<cite>Li G., Kakarla R., Gerritz S. W.. A fast and efficient bromination
of isoxazoles and pyrazoles by microwave irradiation. Tetrahedron Lett. 2007;48:4595–4599. doi: 10.1016/j.tetlet.2007.04.118.</cite> [<a href="https://doi.org/10.1016/j.tetlet.2007.04.118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tetrahedron%20Lett.&amp;title=A%20fast%20and%20efficient%20bromination%20of%20isoxazoles%20and%20pyrazoles%20by%20microwave%20irradiation&amp;author=G.%20Li&amp;author=R.%20Kakarla&amp;author=S.%20W.%20Gerritz&amp;volume=48&amp;publication_year=2007&amp;pages=4595-4599&amp;doi=10.1016/j.tetlet.2007.04.118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref30">
<cite>Leggio A., Bagalà J., Belsito E. L., Comandè A., Greco M., Liguori A.. Formation of amides: One-pot condensation
of carboxylic acids and amines mediated by TiCl4. Chem. Cent. J. 2017;11:87. doi: 10.1186/s13065-017-0318-9.</cite> [<a href="https://doi.org/10.1186/s13065-017-0318-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5602818/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29086872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem.%20Cent.%20J.&amp;title=Formation%20of%20amides:%20One-pot%20condensation%20of%20carboxylic%20acids%20and%20amines%20mediated%20by%20TiCl4&amp;author=A.%20Leggio&amp;author=J.%20Bagal%C3%A0&amp;author=E.%20L.%20Belsito&amp;author=A.%20Comand%C3%A8&amp;author=M.%20Greco&amp;volume=11&amp;publication_year=2017&amp;pages=87&amp;pmid=29086872&amp;doi=10.1186/s13065-017-0318-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref31">
<cite>Dieter R. K., Sharma R. R., Yu H., Gore V. K.. Acylation of α-(N-carbamoyl)
alkylcuprates and alkyl-or aryl (halo)­cuprates. Tetrahedron. 2003;59:1083–1094. doi: 10.1016/S0040-4020(02)01526-0.</cite> [<a href="https://doi.org/10.1016/S0040-4020(02)01526-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tetrahedron&amp;title=Acylation%20of%20%CE%B1-(N-carbamoyl)%20alkylcuprates%20and%20alkyl-or%20aryl%20(halo)%C2%ADcuprates&amp;author=R.%20K.%20Dieter&amp;author=R.%20R.%20Sharma&amp;author=H.%20Yu&amp;author=V.%20K.%20Gore&amp;volume=59&amp;publication_year=2003&amp;pages=1083-1094&amp;doi=10.1016/S0040-4020(02)01526-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref32">
<cite>Wu X., He C., Wu X., Qu S., Duan C.. An L-proline functionalized
metallo-organic triangle as size-selective homogeneous catalyst for
asymmetry catalyzing aldol reactions. Chem.
Commun. 2011;47:8415–8417. doi: 10.1039/c1cc11698c.</cite> [<a href="https://doi.org/10.1039/c1cc11698c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21701751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem.%20Commun.&amp;title=An%20L-proline%20functionalized%20metallo-organic%20triangle%20as%20size-selective%20homogeneous%20catalyst%20for%20asymmetry%20catalyzing%20aldol%20reactions&amp;author=X.%20Wu&amp;author=C.%20He&amp;author=X.%20Wu&amp;author=S.%20Qu&amp;author=C.%20Duan&amp;volume=47&amp;publication_year=2011&amp;pages=8415-8417&amp;pmid=21701751&amp;doi=10.1039/c1cc11698c&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref33">
<cite>Malinauskienė V., Kveselytė A., Dzedulionytė K., Bieliauskas A., Burinskas S., Slo̷k F. A., Šačkus A.. L-Proline
and related chiral heterocyclic amino acids as scaffolds for the synthesis
of functionalized 2-amino-1,3-selenazole-5-carboxylates. Chem. Heterocycl. Compd. 2018;54:469–473. doi: 10.1007/s10593-018-2291-1.</cite> [<a href="https://doi.org/10.1007/s10593-018-2291-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem.%20Heterocycl.%20Compd.&amp;title=L-Proline%20and%20related%20chiral%20heterocyclic%20amino%20acids%20as%20scaffolds%20for%20the%20synthesis%20of%20functionalized%202-amino-1,3-selenazole-5-carboxylates&amp;author=V.%20Malinauskien%C4%97&amp;author=A.%20Kveselyt%C4%97&amp;author=K.%20Dzedulionyt%C4%97&amp;author=A.%20Bieliauskas&amp;author=S.%20Burinskas&amp;volume=54&amp;publication_year=2018&amp;pages=469-473&amp;doi=10.1007/s10593-018-2291-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref34">
<cite>Teegarden B. R., Li H., Jayakumar H., Strah-Pleynet S., Dosa P. I., Selaya S. D., Kato N., Elwell K. H., Davidson J., Cheng K., Saldana H., Frazer J. M., Whelan K., Foster J., Espitia S., Webb R. W., Beeley N. R. A., Thomsen W., Morairty S. R., Kilduff S. T., Al-Shamma H. A.. Discovery
of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)­urea
(Nelotanserin) and Related 5-Hydroxytryptamine2A Inverse Agonists
for the Treatment of Insomnia. J. Med. Chem. 2010;53:1923–1936. doi: 10.1021/jm9007328.</cite> [<a href="https://doi.org/10.1021/jm9007328" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20143782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Discovery%20of%201-%5B3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl%5D-3-(2,4-difluorophenyl)%C2%ADurea%20(Nelotanserin)%20and%20Related%205-Hydroxytryptamine2A%20Inverse%20Agonists%20for%20the%20Treatment%20of%20Insomnia&amp;author=B.%20R.%20Teegarden&amp;author=H.%20Li&amp;author=H.%20Jayakumar&amp;author=S.%20Strah-Pleynet&amp;author=P.%20I.%20Dosa&amp;volume=53&amp;publication_year=2010&amp;pages=1923-1936&amp;pmid=20143782&amp;doi=10.1021/jm9007328&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref35">
<cite>Jayaram V., Sridhar T., Sharma G. V. M., Berrée F., Carboni B.. Synthesis of 1-Amino-1H-Indenes
via a Sequential Suzuki–Miyaura
Coupling/Petasis Condensation Sequence. J. Org.
Chem. 2017;82:1803–1811. doi: 10.1021/acs.joc.6b02549.</cite> [<a href="https://doi.org/10.1021/acs.joc.6b02549" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28056174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Org.%20Chem.&amp;title=Synthesis%20of%201-Amino-1H-Indenes%20via%20a%20Sequential%20Suzuki%E2%80%93Miyaura%20Coupling/Petasis%20Condensation%20Sequence&amp;author=V.%20Jayaram&amp;author=T.%20Sridhar&amp;author=G.%20V.%20M.%20Sharma&amp;author=F.%20Berr%C3%A9e&amp;author=B.%20Carboni&amp;volume=82&amp;publication_year=2017&amp;pages=1803-1811&amp;pmid=28056174&amp;doi=10.1021/acs.joc.6b02549&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref36">
<cite>Cockram P. E., Turner C. A., Slawin A. M. Z., Smith T. K.. Convenient Synthesis
of Alternatively Bridged Tryptophan Ketopiperazines and Their Activities
against Trypanosomatid Parasites. Chem. Med.
Chem. 2022;17:e202100664.  doi: 10.1002/cmdc.202100664.</cite> [<a href="https://doi.org/10.1002/cmdc.202100664" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34927802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chem.%20Med.%20Chem.&amp;title=Convenient%20Synthesis%20of%20Alternatively%20Bridged%20Tryptophan%20Ketopiperazines%20and%20Their%20Activities%20against%20Trypanosomatid%20Parasites&amp;author=P.%20E.%20Cockram&amp;author=C.%20A.%20Turner&amp;author=A.%20M.%20Z.%20Slawin&amp;author=T.%20K.%20Smith&amp;volume=17&amp;publication_year=2022&amp;pages=e202100664&amp;pmid=34927802&amp;doi=10.1002/cmdc.202100664&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref37">
<cite>Falorni M., Giacomelli G., Spanedda A. M.. Synthesis of chiral
pyrazoles and
isoxazoles as constrained amino acids. Tetrahedron. 1998;9:3039–3046. doi: 10.1016/S0957-4166(98)00305-X.</cite> [<a href="https://doi.org/10.1016/S0957-4166(98)00305-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tetrahedron&amp;title=Synthesis%20of%20chiral%20pyrazoles%20and%20isoxazoles%20as%20constrained%20amino%20acids&amp;author=M.%20Falorni&amp;author=G.%20Giacomelli&amp;author=A.%20M.%20Spanedda&amp;volume=9&amp;publication_year=1998&amp;pages=3039-3046&amp;doi=10.1016/S0957-4166(98)00305-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref38">
<cite>Bagley C., Lubinu M. C., Mason C.. Regioselective
Microwave-Assisted
Synthesis of Substituted Pyrazoles from Ethynyl Ketones. Synlett. 2007;5:704–708. doi: 10.1055/s-2007-970783.</cite> [<a href="https://doi.org/10.1055/s-2007-970783" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Synlett&amp;title=Regioselective%20Microwave-Assisted%20Synthesis%20of%20Substituted%20Pyrazoles%20from%20Ethynyl%20Ketones&amp;author=C.%20Bagley&amp;author=M.%20C.%20Lubinu&amp;author=C.%20Mason&amp;volume=5&amp;publication_year=2007&amp;pages=704-708&amp;doi=10.1055/s-2007-970783&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref39">
<cite>Reddy G. J., Latha D., Rao K. S.. A clean
and rapid synthesis of 5-amino
and 5-alkoxycarbonylpyrazoles using montomorillonite under acid free
conditions. Org. Prep. Proced. Int. 2004;36:494–498. doi: 10.1080/00304940409356638.</cite> [<a href="https://doi.org/10.1080/00304940409356638" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Org.%20Prep.%20Proced.%20Int.&amp;title=A%20clean%20and%20rapid%20synthesis%20of%205-amino%20and%205-alkoxycarbonylpyrazoles%20using%20montomorillonite%20under%20acid%20free%20conditions&amp;author=G.%20J.%20Reddy&amp;author=D.%20Latha&amp;author=K.%20S.%20Rao&amp;volume=36&amp;publication_year=2004&amp;pages=494-498&amp;doi=10.1080/00304940409356638&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref40">
<cite>Ningaiah S., Bhadraiah U. K., Basavanna V., Lingegowda V. S., Shanthakumar D. C., Doddamani S.. Novel pyrazolyl-thiazoles: synthesis,
characterization and study of their antidiabetic Properties. Biointerface Res. Appl. Chem. 2020;10:5849–5854. doi: 10.33263/BRIAC104.849854.</cite> [<a href="https://doi.org/10.33263/BRIAC104.849854" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biointerface%20Res.%20Appl.%20Chem.&amp;title=Novel%20pyrazolyl-thiazoles:%20synthesis,%20characterization%20and%20study%20of%20their%20antidiabetic%20Properties&amp;author=S.%20Ningaiah&amp;author=U.%20K.%20Bhadraiah&amp;author=V.%20Basavanna&amp;author=V.%20S.%20Lingegowda&amp;author=D.%20C.%20Shanthakumar&amp;volume=10&amp;publication_year=2020&amp;pages=5849-5854&amp;doi=10.33263/BRIAC104.849854&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref41">
<cite>Kopp M., Lancelot J., Dallemagne P., Rault S.. Synthesis of novel
pyrazolopyrrolopyrazines, potential analogs of sildenafil. J. Heterocycl. Chem. 2001;38:1045–1050. doi: 10.1002/jhet.5570380506.</cite> [<a href="https://doi.org/10.1002/jhet.5570380506" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Heterocycl.%20Chem.&amp;title=Synthesis%20of%20novel%20pyrazolopyrrolopyrazines,%20potential%20analogs%20of%20sildenafil&amp;author=M.%20Kopp&amp;author=J.%20Lancelot&amp;author=P.%20Dallemagne&amp;author=S.%20Rault&amp;volume=38&amp;publication_year=2001&amp;pages=1045-1050&amp;doi=10.1002/jhet.5570380506&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref42">
<cite>Neschadim A., Branch D. R.. Mouse models for immune-mediated platelet destruction
or immune thrombocytopenia (ITP) Curr. Protoc.
Immunol. 2016;113:15301.1–1530.13. doi: 10.1002/0471142735.im1530s113.</cite> [<a href="https://doi.org/10.1002/0471142735.im1530s113" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27038460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr.%20Protoc.%20Immunol.&amp;title=Mouse%20models%20for%20immune-mediated%20platelet%20destruction%20or%20immune%20thrombocytopenia%20(ITP)&amp;author=A.%20Neschadim&amp;author=D.%20R.%20Branch&amp;volume=113&amp;publication_year=2016&amp;pages=15301.1-1530.13&amp;pmid=27038460&amp;doi=10.1002/0471142735.im1530s113&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref43">
<cite>Neschadim A., Branch D. R.. Mouse models of
autoimmune diseases: immune thrombocytopenia. Curr. Pharm. Des. 2015;21:2487–2497. doi: 10.2174/1381612821666150316123436.</cite> [<a href="https://doi.org/10.2174/1381612821666150316123436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25777762/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr.%20Pharm.%20Des.&amp;title=Mouse%20models%20of%20autoimmune%20diseases:%20immune%20thrombocytopenia&amp;author=A.%20Neschadim&amp;author=D.%20R.%20Branch&amp;volume=21&amp;publication_year=2015&amp;pages=2487-2497&amp;pmid=25777762&amp;doi=10.2174/1381612821666150316123436&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref44">
<cite>Chow L., Aslam R., Speck E. R., Kim M., Cridland N., Webster M. L., Chen P., Sahib K., Ni H., Lazarus A. H., Garvey M. B., Freedman J., Semple J. W.. A murine
model of severe immune thrombocytopenia is induced by antibody- and
CD8+ T cell-mediated responses that are differentially sensitive to
therapy. Blood. 2010;115:1247–1253. doi: 10.1182/blood-2009-09-244772.</cite> [<a href="https://doi.org/10.1182/blood-2009-09-244772" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20007808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20murine%20model%20of%20severe%20immune%20thrombocytopenia%20is%20induced%20by%20antibody-%20and%20CD8+%20T%20cell-mediated%20responses%20that%20are%20differentially%20sensitive%20to%20therapy&amp;author=L.%20Chow&amp;author=R.%20Aslam&amp;author=E.%20R.%20Speck&amp;author=M.%20Kim&amp;author=N.%20Cridland&amp;volume=115&amp;publication_year=2010&amp;pages=1247-1253&amp;pmid=20007808&amp;doi=10.1182/blood-2009-09-244772&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref45">
<cite>Katsman Y., Foo A. H., Leontyev D., Branch D. R.. Improved mouse models
for the study of treatment modalities for immune-mediated platelet
destruction. Transfusion. 2010;50:1285–1294. doi: 10.1111/j.1537-2995.2009.02558.x.</cite> [<a href="https://doi.org/10.1111/j.1537-2995.2009.02558.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20088841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transfusion&amp;title=Improved%20mouse%20models%20for%20the%20study%20of%20treatment%20modalities%20for%20immune-mediated%20platelet%20destruction&amp;author=Y.%20Katsman&amp;author=A.%20H.%20Foo&amp;author=D.%20Leontyev&amp;author=D.%20R.%20Branch&amp;volume=50&amp;publication_year=2010&amp;pages=1285-1294&amp;pmid=20088841&amp;doi=10.1111/j.1537-2995.2009.02558.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref46">
<cite>Leontyev D., Katsman Y., Branch D. R.. Mouse background
and IVIG dosage
are critical in establishing the role of inhibitory Fcγ receptor
for the amelioration of experimental ITP. Blood. 2012;119:5261–5264. doi: 10.1182/blood-2012-03-415695.</cite> [<a href="https://doi.org/10.1182/blood-2012-03-415695" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22508937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Mouse%20background%20and%20IVIG%20dosage%20are%20critical%20in%20establishing%20the%20role%20of%20inhibitory%20Fc%CE%B3%20receptor%20for%20the%20amelioration%20of%20experimental%20ITP&amp;author=D.%20Leontyev&amp;author=Y.%20Katsman&amp;author=D.%20R.%20Branch&amp;volume=119&amp;publication_year=2012&amp;pages=5261-5264&amp;pmid=22508937&amp;doi=10.1182/blood-2012-03-415695&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref47">
<cite>Leontyev D., Katsman Y., Ma X., Miescher S., Käsermann F., Branch D. R.. Sialylation-independent
mechanism involved in the amelioration
of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion. 2012;52:1799–1805. doi: 10.1111/j.1537-2995.2011.03517.x.</cite> [<a href="https://doi.org/10.1111/j.1537-2995.2011.03517.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22257295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transfusion&amp;title=Sialylation-independent%20mechanism%20involved%20in%20the%20amelioration%20of%20murine%20immune%20thrombocytopenia%20using%20intravenous%20gammaglobulin&amp;author=D.%20Leontyev&amp;author=Y.%20Katsman&amp;author=X.%20Ma&amp;author=S.%20Miescher&amp;author=F.%20K%C3%A4sermann&amp;volume=52&amp;publication_year=2012&amp;pages=1799-1805&amp;pmid=22257295&amp;doi=10.1111/j.1537-2995.2011.03517.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref48">
<cite>McMillan R.. Autoantibodies
and autoantigens in chronic immune thrombocytopenic purpura. Semin. Hematol. 2000;37:239–248. doi: 10.1016/S0037-1963(00)90102-1.</cite> [<a href="https://doi.org/10.1016/S0037-1963(00)90102-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10942218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin.%20Hematol.&amp;title=Autoantibodies%20and%20autoantigens%20in%20chronic%20immune%20thrombocytopenic%20purpura&amp;author=R.%20McMillan&amp;volume=37&amp;publication_year=2000&amp;pages=239-248&amp;pmid=10942218&amp;doi=10.1016/S0037-1963(00)90102-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref49">
<cite>Siragam V., Brinc D., Crow A. R., Song S., Freedman J., Lazarus A. H.. Can antibodies with specificity for
soluble antigens
mimic the therapeutic effects of intravenous IgG in the treatment
of autoimmune disease? J. Clin. Invest. 2005;115:155–160. doi: 10.1172/JCI200522753.</cite> [<a href="https://doi.org/10.1172/JCI200522753" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC539200/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15630455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Invest.&amp;title=Can%20antibodies%20with%20specificity%20for%20soluble%20antigens%20mimic%20the%20therapeutic%20effects%20of%20intravenous%20IgG%20in%20the%20treatment%20of%20autoimmune%20disease?&amp;author=V.%20Siragam&amp;author=D.%20Brinc&amp;author=A.%20R.%20Crow&amp;author=S.%20Song&amp;author=J.%20Freedman&amp;volume=115&amp;publication_year=2005&amp;pages=155-160&amp;pmid=15630455&amp;doi=10.1172/JCI200522753&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref50">
<cite>Loriamini M., Lewis-Bakker M. M., Binnington B., Kotra L. P., Branch D. R.. A novel
small molecule phagocytosis inhibitor, KB-208, ameliorates ITP in
mouse models with similar efficacy as IVIG. Transfusion. 2024;64:2233–2240. doi: 10.1111/trf.18060.</cite> [<a href="https://doi.org/10.1111/trf.18060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11637249/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39511877/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transfusion&amp;title=A%20novel%20small%20molecule%20phagocytosis%20inhibitor,%20KB-208,%20ameliorates%20ITP%20in%20mouse%20models%20with%20similar%20efficacy%20as%20IVIG&amp;author=M.%20Loriamini&amp;author=M.%20M.%20Lewis-Bakker&amp;author=B.%20Binnington&amp;author=L.%20P.%20Kotra&amp;author=D.%20R.%20Branch&amp;volume=64&amp;publication_year=2024&amp;pages=2233-2240&amp;pmid=39511877&amp;doi=10.1111/trf.18060&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref51">
<cite>Tong T. N., Branch D. R.. Use of a Monocyte
Monolayer Assay to Evaluate Fcγ
Receptor-mediated Phagocytosis. J. Vis. Exp. 2017;119:55039.  doi: 10.3791/55039.</cite> [<a href="https://doi.org/10.3791/55039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5408648/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28117787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Vis.%20Exp.&amp;title=Use%20of%20a%20Monocyte%20Monolayer%20Assay%20to%20Evaluate%20Fc%CE%B3%20Receptor-mediated%20Phagocytosis&amp;author=T.%20N.%20Tong&amp;author=D.%20R.%20Branch&amp;volume=119&amp;publication_year=2017&amp;pages=55039&amp;pmid=28117787&amp;doi=10.3791/55039&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12332598/bin/ao5c03645_si_001.pdf" data-ga-action="click_feat_suppl" class="usa-link">ao5c03645_si_001.pdf</a><sup> (2.2MB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from ACS Omega are provided here courtesy of <strong>American Chemical Society</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1021/acsomega.5c03645"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/ao5c03645.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12332598/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12332598/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12332598%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12332598/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12332598/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12332598/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40787340/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12332598/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40787340/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12332598/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12332598/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="2sLjpKFXLYgVYZ9xRGCgkRB2JXBKHGNiBZo88T3RIMeyrH2JYsa6bs2JsnRpBlVB">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-d9849939.js"></script>
    
    

    </body>
</html>
